<SEC-DOCUMENT>0001811884-23-000013.txt : 20230505
<SEC-HEADER>0001811884-23-000013.hdr.sgml : 20230505
<ACCEPTANCE-DATETIME>20230505122205
ACCESSION NUMBER:		0001811884-23-000013
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		43
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230505
DATE AS OF CHANGE:		20230505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		23892363

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>utmd-20230331.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='us-ascii' standalone='no'?>
<html xmlns='http://www.w3.org/1999/xhtml' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:dei='http://xbrl.sec.gov/dei/2023' xmlns:dtr-types='http://www.xbrl.org/dtr/type/2022-03-31' xmlns:us-gaap='http://fasb.org/us-gaap/2023' xmlns:srt='http://fasb.org/srt/2023' xmlns:fil='http://www.utahmed.com/20230331' xmlns:i='http://www.xbrl.org/2003/instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:ix='http://www.xbrl.org/2013/inlineXBRL' xmlns:ixt='http://www.xbrl.org/inlineXBRL/transformation/2015-02-26' xmlns:ixt-sec='http://www.sec.gov/inlineXBRL/transformation/2015-08-31' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance'>
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVD9NVDXT]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS INC - Form 10-Q SEC filing</title>
<meta content='text/html; charset=UTF-8' http-equiv='Content-Type' />
</head>
<body>
<div style='display:none'>
<ix:header>
<ix:hidden>
<ix:nonNumeric name='dei:EntityCentralIndexKey' contextRef='Y23Q1' id='fact1'>0000706698</ix:nonNumeric>
<ix:nonNumeric name='dei:CurrentFiscalYearEndDate' contextRef='Y23Q1' id='fact2'>--12-31</ix:nonNumeric>
<ix:nonNumeric name='dei:EntityCurrentReportingStatus' contextRef='Y23Q1' id='fact3'>Yes</ix:nonNumeric>
<ix:nonNumeric name='dei:AmendmentFlag' contextRef='Y23Q1' id='fact4'>false</ix:nonNumeric>
<ix:nonNumeric name='dei:DocumentFiscalYearFocus' contextRef='Y23Q1' id='fact5'>2023</ix:nonNumeric>
<ix:nonNumeric name='dei:DocumentFiscalPeriodFocus' contextRef='Y23Q1' id='fact6'>Q1</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole='http://www.xbrl.org/2003/linkbase' xlink:href='utmd-20230331.xsd' xlink:type='simple'/>
</ix:references>
<ix:resources>
<i:context id='Y23Q1'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='E23Q1'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id='I230504'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2023-05-04</i:instant>
</i:period>
</i:context>
<i:context id='E22'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id='Y22Q1'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='E21'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E22Q1'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2022-03-31</i:instant>
</i:period>
</i:context>
<i:context id='Y23Q1_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='E22_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E22_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E22_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E22_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E23Q1_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E23Q1_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E23Q1_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E23Q1_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2023-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E21_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E21_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E21_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E21_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2021-12-31</i:instant>
</i:period>
</i:context>
<i:context id='Y22Q1_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q1_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q1_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y22Q1_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2022-01-01</i:startDate>
<i:endDate>2022-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='E22Q1_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E22Q1_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E22Q1_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-03-31</i:instant>
</i:period>
</i:context>
<i:context id='E22Q1_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2022-03-31</i:instant>
</i:period>
</i:context>
<i:context id='Y23Q1_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_ProductOrService-Obstetrics'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_ProductOrService-Obstetrics_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_ProductOrService-Obstetrics_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_ProductOrService-GynecologyElectrosurgeryUrology'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_ProductOrService-Neonatal'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_ProductOrService-Neonatal_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_ProductOrService-Neonatal_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_ProductOrService-BloodPressureMonitoringAndAccessories'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y23Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-01-01</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='fil:DistributionRightsAcquisitionAxis'>fil:CoopersurgicalIncMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-01-01</i:startDate>
<i:endDate>2019-03-31</i:endDate>
</i:period>
</i:context>
<i:context id='D230331_DistributionRightsAcquisition-CoopersurgicalInc'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='fil:DistributionRightsAcquisitionAxis'>fil:CoopersurgicalIncMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2023-03-31</i:startDate>
<i:endDate>2023-03-31</i:endDate>
</i:period>
</i:context>
<i:unit id='Pure'>
<i:measure>xbrli:pure</i:measure>
</i:unit>
<i:unit id='USD'>
<i:measure>iso4217:USD</i:measure>
</i:unit>
<i:unit id='Shares'>
<i:measure>xbrli:shares</i:measure>
</i:unit>
<i:unit id='UsdPerShare'>
<i:divide>
<i:unitNumerator>
<i:measure>iso4217:USD</i:measure>
</i:unitNumerator>
<i:unitDenominator>
<i:measure>xbrli:shares</i:measure>
</i:unitDenominator>
</i:divide>
</i:unit>
</ix:resources>
</ix:header>
</div>
<div><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>UNITED STATES</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>SECURITIES AND EXCHANGE COMMISSION</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>Washington, D.C. &#160;20549</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>FORM<b> </b><ix:nonNumeric name='dei:DocumentType' contextRef='Y23Q1' escape='true'>10-Q</ix:nonNumeric></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top'><p style='font:10pt Times New Roman;margin:0'><span style='font-family:MS Gothic'><ix:nonNumeric name='dei:DocumentQuarterlyReport' contextRef='Y23Q1' format='ixt-sec:boolballotbox'>&#9746;</ix:nonNumeric></span> &#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>For the quarterly period ended <ix:nonNumeric name='dei:DocumentPeriodEndDate' contextRef='Y23Q1' format='ixt:datemonthdayyearen'>March 31, 2023</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>OR</p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0'><span style='font-family:MS Gothic'><ix:nonNumeric name='dei:DocumentTransitionReport' contextRef='Y23Q1' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></span> &#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>For the transition period from  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Commission File No. <span style='border-bottom:1px solid #000000'><ix:nonNumeric name='dei:EntityFileNumber' contextRef='Y23Q1' escape='true'>001-12575</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'><ix:nonNumeric name='dei:EntityRegistrantName' contextRef='Y23Q1' escape='true'>UTAH MEDICAL PRODUCTS INC</ix:nonNumeric></span></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>(Exact name of Registrant as specified in its charter)</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'><ix:nonNumeric name='dei:EntityIncorporationStateCountryCode' contextRef='Y23Q1' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></span></p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityTaxIdentificationNumber' contextRef='Y23Q1' escape='true'>87-0342734</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(State or other jurisdiction of incorporation or organization)</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(I.R.S. Employer&#160;Identification No.)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityAddressAddressLine1' contextRef='Y23Q1' escape='true'>7043 South 300 West</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'><ix:nonNumeric name='dei:EntityAddressCityOrTown' contextRef='Y23Q1' escape='true'>Midvale</ix:nonNumeric>, <ix:nonNumeric name='dei:EntityAddressStateOrProvince' contextRef='Y23Q1' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric> &#160;<ix:nonNumeric name='dei:EntityAddressPostalZipCode' contextRef='Y23Q1' escape='true'>84047</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(Address of principal executive offices) (Zip Code)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>(<ix:nonNumeric name='dei:CityAreaCode' contextRef='Y23Q1' escape='true'>801</ix:nonNumeric>) </span><ix:nonNumeric name='dei:LocalPhoneNumber' contextRef='Y23Q1' escape='true'>566-1200</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(Registrant&#8217;s telephone number, including area code)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top'><p style='font:10pt Times New Roman;margin:0'>Securities registered pursuant to Section 12(b) of the Act:</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Title of each class:</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Trading Symbol:</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Name of each exchange on which registered:</p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:Security12bTitle' contextRef='Y23Q1' escape='true'>Common stock, $0.01 par value</ix:nonNumeric></p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:TradingSymbol' contextRef='Y23Q1' escape='true'>UTMD</ix:nonNumeric></p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:SecurityExchangeName' contextRef='Y23Q1' escape='true'>NASDAQ</ix:nonNumeric></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;<span style='-sec-ix-hidden:fact3'>Yes</span>&#160;<span style='font-family:MS Gothic'>&#9746;</span> &#160;&#160;No&#160;<span style='font-family:MS Gothic'>&#9744;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;<ix:nonNumeric name='dei:EntityInteractiveDataCurrent' contextRef='Y23Q1' escape='true'>Yes</ix:nonNumeric>&#160;<span style='font-family:MS Gothic'>&#9746;</span> &#160;&#160;No&#160;<span style='font-family:MS Gothic'>&#9744;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top'><p style='font:10pt Times New Roman;margin:0'>Large accelerated filer&#160;<span style='font-family:MS Gothic'>&#9744;</span></p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>Accelerated filer&#160;<span style='font-family:MS Gothic'>&#9744;</span></p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0'><ix:nonNumeric name='dei:EntityFilerCategory' contextRef='Y23Q1' format='ixt-sec:entityfilercategoryen'>Non-accelerated filer</ix:nonNumeric> <span style='font-family:MS Gothic'>&#9746;</span></p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>Smaller reporting company <span style='font-family:MS Gothic'><ix:nonNumeric name='dei:EntitySmallBusiness' contextRef='Y23Q1' format='ixt-sec:boolballotbox'>&#9746;</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>Emerging growth company <span style='font-family:MS Gothic'><ix:nonNumeric name='dei:EntityEmergingGrowthCompany' contextRef='Y23Q1' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style='font-family:MS Gothic'>&#9744;</span> &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;Yes&#160;<span style='font-family:MS Gothic'><ix:nonNumeric name='dei:EntityShellCompany' contextRef='Y23Q1' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></span> &#160;&#160;No&#160;<span style='font-family:MS Gothic'>&#9746;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock as of May 4, 2023: <ix:nonFraction name='dei:EntityCommonStockSharesOutstanding' contextRef='I230504' unitRef='Shares' decimals='INF' scale='0' format='ixt:numdotdecimal'>3,628,067</ix:nonFraction>.&#160;</p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a2'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>INDEX TO FORM 10-Q</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>PAGE</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a4' style='text-decoration:none'>PART I - FINANCIAL INFORMATION</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a4' style='text-decoration:none'>Item 1.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a4' style='text-decoration:none'>Financial Statements</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a5' style='text-decoration:none'>Consolidated Condensed Balance Sheets as of March 31, 2023 and December 31, 2022</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a6' style='text-decoration:none'>Consolidated Condensed Statements of Income for the three months ended March 31, 2023 and March 31, 2022</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:42.3pt'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a7' style='text-decoration:none'>Consolidated Condensed Statements of Cash Flows for the three months ended March 31, 2023 and March 31, 2022</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>3</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:42.3pt'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a8' style='text-decoration:none'>Consolidated Condensed Statements of Stockholders&#8217; Equity for the three months ended March 31, 2023 and March 31, 2022</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>4</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a9' style='text-decoration:none'>Notes to Consolidated Condensed Financial Statements</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>5</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a10' style='text-decoration:none'>Item 2.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:42.3pt'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a10' style='text-decoration:none'>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>7</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a11' style='text-decoration:none'>Item 3.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a11' style='text-decoration:none'>Quantitative and Qualitative Disclosures About Market Risk</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>14</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a12' style='text-decoration:none'>Item 4.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a12' style='text-decoration:none'>Controls and Procedures</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>14</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a13' style='text-decoration:none'>PART II &#8211;&#160;OTHER INFORMATION</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a14' style='text-decoration:none'>Item 1.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a14' style='text-decoration:none'>Legal Proceedings</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>15</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a15' style='text-decoration:none'>Item 1A.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a15' style='text-decoration:none'>Risk Factors</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>15</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a16' style='text-decoration:none'>Item 2.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a16' style='text-decoration:none'>Unregistered Sales of Equity Securities and Use of Proceeds</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>16</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a17' style='text-decoration:none'>Item 6.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a17' style='text-decoration:none'>Exhibits</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>16</p>
</td></tr>
<tr><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a18' style='text-decoration:none'>SIGNATURES</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>17</p>
</td></tr>
</table>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a4'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>PART I - FINANCIAL INFORMATION</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><b>Item 1. Financial Statements</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a5'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:11.5pt'><td colspan='4' valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style='height:11.5pt'><td colspan='4' valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED BALANCE SHEETS AS OF</span></p>
</td></tr>
<tr style='height:11.5pt'><td colspan='4' valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>MARCH 31, 2023 AND DECEMBER 31, 2022</span></p>
</td></tr>
<tr style='height:11.5pt'><td colspan='4' valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(in thousands)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(unaudited)</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(audited)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'></td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>MARCH 31, 2023</span></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>DECEMBER 31, 2022</span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><span style='border-bottom:1px solid #000000'>ASSETS</span></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>Current assets:</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Cash &amp; Investments</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$  &#160;&#160;&#160;<ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>80,912</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$  &#160;&#160;&#160;<ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>75,052</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts &amp; other receivables, net</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccountsReceivableNetCurrent' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,818</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccountsReceivableNetCurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,538</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Inventories</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,940</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,814</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Other current assets</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherAssetsCurrent' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>442</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherAssetsCurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>515</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total current assets</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AssetsCurrent' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>95,112</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AssetsCurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>89,919</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>Property and equipment, net</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PropertyPlantAndEquipmentNet' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,241</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PropertyPlantAndEquipmentNet' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,224</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Goodwill</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Goodwill' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,502</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Goodwill' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,354</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Other intangible assets</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsGross' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>53,443</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsGross' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>52,755</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Other intangible assets - accumulated amortization</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>44,528</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>42,378</ix:nonFraction>)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>Other intangible assets, net</p>
</td><td valign='bottom' style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IntangibleAssetsNetExcludingGoodwill' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,915</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IntangibleAssetsNetExcludingGoodwill' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,377</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total assets</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:Assets' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>127,770</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:Assets' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>123,874</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><span style='border-bottom:1px solid #000000'>LIABILITIES AND STOCKHOLDERS' EQUITY</span></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>Current liabilities:</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts payable</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:AccountsPayableCurrent' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,028</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:AccountsPayableCurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,218</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accrued expenses</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccruedLiabilitiesCurrent' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,046</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccruedLiabilitiesCurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,742</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total current liabilities</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:LiabilitiesCurrent' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,074</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:LiabilitiesCurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,960</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Deferred tax liability &#8211; Femcare IIA</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,456</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,514</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Other long term liabilities</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherLiabilitiesNoncurrent' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,256</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherLiabilitiesNoncurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,256</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Long-term lease liability</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseLiabilityNoncurrent' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>328</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseLiabilityNoncurrent' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>341</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>Deferred income taxes</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredIncomeTaxLiabilitiesNet' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>638</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredIncomeTaxLiabilitiesNet' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>549</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total liabilities</p>
</td><td valign='bottom' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Liabilities' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,752</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Liabilities' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,620</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>Stockholders' equity:</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Common stock - $<ix:nonFraction name='us-gaap:CommonStockParOrStatedValuePerShare' contextRef='E23Q1' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockParOrStatedValuePerShare' contextRef='E22' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.01</ix:nonFraction></ix:nonFraction> par value; authorized - <ix:nonFraction name='us-gaap:CommonStockSharesAuthorized' contextRef='E23Q1' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockSharesAuthorized' contextRef='E22' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>50,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding - March 31, 2023, <ix:nonFraction name='us-gaap:CommonStockSharesIssued' contextRef='E23Q1' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockSharesOutstanding' contextRef='E23Q1' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,628</ix:nonFraction></ix:nonFraction> shares and December 31, 2022, <ix:nonFraction name='us-gaap:CommonStockSharesIssued' contextRef='E22' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockSharesOutstanding' contextRef='E22' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,628</ix:nonFraction></ix:nonFraction> shares</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CommonStockValue' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CommonStockValue' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accumulated other comprehensive loss</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1' contextRef='E23Q1' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,490</ix:nonFraction>)</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1' contextRef='E22' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,039</ix:nonFraction>)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Additional paid-in capital</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdditionalPaidInCapitalCommonStock' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>322</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdditionalPaidInCapitalCommonStock' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>251</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Retained earnings</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RetainedEarningsAccumulatedDeficit' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>129,150</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RetainedEarningsAccumulatedDeficit' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>126,006</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total stockholders' equity</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>118,018</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>114,254</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total liabilities and stockholders' equity</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:LiabilitiesAndStockholdersEquity' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>127,770</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:LiabilitiesAndStockholdersEquity' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>123,874</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:8pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>1</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a6'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:11.5pt'><td colspan='4' valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style='height:11.5pt'><td colspan='4' valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE</span></p>
</td></tr>
<tr style='height:11.5pt'><td colspan='4' valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>THREE MONTHS ENDED MARCH 31, 2023 AND MARCH 31, 2022</span></p>
</td></tr>
<tr style='height:11.5pt'><td colspan='4' valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(in thousands, except per share amounts - unaudited)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td colspan='3' valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>THREE MONTHS ENDED</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>MARCH 31,</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'></td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2023</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2022</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Sales, net</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,520</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,323</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Cost of goods sold</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,677</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,790</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Gross profit</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,843</ix:nonFraction></p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,533</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating expense</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Selling, general and administrative</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,260</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,888</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Research &amp; development</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>144</ix:nonFraction></p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>123</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total operating expenses</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,404</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,011</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Operating income</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,439</ix:nonFraction></p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,522</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other income</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>680</ix:nonFraction></p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Income before provision for income taxes</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,119</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,530</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Provision for income taxes</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>905</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>996</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net income</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,214</ix:nonFraction></p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,534</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per common share (basic)</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y23Q1' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.16</ix:nonFraction></p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y22Q1' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.97</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per common share (diluted)</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y23Q1' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.16</ix:nonFraction></p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y22Q1' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.96</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Shares outstanding (basic)</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y23Q1' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,628</ix:nonFraction></p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y22Q1' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,655</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Shares outstanding (diluted)</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y23Q1' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,636</ix:nonFraction></p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y22Q1' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,665</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other comprehensive income (loss):</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Foreign currency translation net of taxes of $<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='Y23Q1' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='Y22Q1' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='Y23Q1' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='Y22Q1' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'>0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in all periods</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160; &#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>549</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160; &#160;(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q1' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>506</ix:nonFraction>)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total comprehensive income</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,763</ix:nonFraction></p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,028</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;margin-left:38.9pt'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>2</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a7'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:11.5pt'><td colspan='5' valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style='height:11.5pt'><td colspan='5' valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS</span></p>
</td></tr>
<tr style='height:11.5pt'><td colspan='5' valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>FOR THE THREE MONTHS ENDED MARCH 31, 2023 AND MARCH 31, 2022</span></p>
</td></tr>
<tr style='height:11.5pt'><td colspan='5' valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(in thousands - unaudited)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td colspan='3' valign='bottom' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>THREE MONTHS ENDED</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>MARCH 31,</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'></td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2023</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2022</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>CASH FLOWS FROM OPERATING ACTIVITIES:</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>Net income</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,214</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,534</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>Adjustments to reconcile net income to net<br/> &#160;cash provided by operating activities:</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Depreciation</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Depreciation' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>155</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Depreciation' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>149</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Amortization</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AmortizationOfIntangibleAssets' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,596</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AmortizationOfIntangibleAssets' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,646</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;margin-left:10.1pt'><span style='font-family:Times New Roman'>Provision for losses on accounts receivable</span></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:ProvisionForDoubtfulAccounts' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1</ix:nonFraction></span></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:ProvisionForDoubtfulAccounts' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8</ix:nonFraction></span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Amortization of right-of-use assets</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>14</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;margin-left:10.1pt'><span style='font-family:Times New Roman'>Deferred income taxes</span></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DeferredIncomeTaxExpenseBenefit' contextRef='Y23Q1' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DeferredIncomeTaxExpenseBenefit' contextRef='Y22Q1' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>144</ix:nonFraction>)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Stock-based compensation expense</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ShareBasedCompensation' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>50</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ShareBasedCompensation' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>43</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Tax benefit attributable to exercise of stock options</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxExpenseFromStockOptionsExercised' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxExpenseFromStockOptionsExercised' contextRef='Y22Q1' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>Changes in operating assets and liabilities:</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts receivable and other receivables</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsReceivable' contextRef='Y23Q1' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,789</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsReceivable' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>578</ix:nonFraction>)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Inventories</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInInventories' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,084</ix:nonFraction>)</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInInventories' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>809</ix:nonFraction>)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Prepaid expenses and other current assets</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' contextRef='Y23Q1' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>25</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>109</ix:nonFraction>)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts payable</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsPayable' contextRef='Y23Q1' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>193</ix:nonFraction>)</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsPayable' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>695</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accrued expenses</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInAccruedLiabilities' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>350</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInAccruedLiabilities' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>597</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total adjustments</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,701</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,512</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net cash provided by operating activities</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:NetCashProvidedByUsedInOperatingActivities' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,915</ix:nonFraction></span></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:NetCashProvidedByUsedInOperatingActivities' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,046</ix:nonFraction></span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>CASH FLOWS FROM INVESTING ACTIVITIES:</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>Capital expenditures for:</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Property and equipment</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsToAcquirePropertyPlantAndEquipment' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>43</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsToAcquirePropertyPlantAndEquipment' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>237</ix:nonFraction>)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net cash used in investing activities</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInInvestingActivities' contextRef='Y23Q1' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>43</ix:nonFraction>)</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInInvestingActivities' contextRef='Y22Q1' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>237</ix:nonFraction>)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>CASH FLOWS FROM FINANCING ACTIVITIES:</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>Proceeds from issuance of common stock - options</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProceedsFromIssuanceOfCommonStock' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>21</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProceedsFromIssuanceOfCommonStock' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>19</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>Payment of dividends</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsOfDividends' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,070</ix:nonFraction>)</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PaymentsOfDividends' contextRef='Y22Q1' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net cash provided by/(used in) financing activities</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInFinancingActivities' contextRef='Y23Q1' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,049</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:NetCashProvidedByUsedInFinancingActivities' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>19</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>Effect of exchange rate changes on cash</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>71</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>Net increase in cash and cash equivalents</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,860</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,899</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>Cash at beginning of period</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>75,052</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>60,974</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>Cash at end of period</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>80,912</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='E22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>65,873</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Cash paid during the period for income taxes</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:IncomeTaxesPaid' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>129</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:IncomeTaxesPaid' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>82</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Cash paid during the period for interest</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InterestPaid' contextRef='Y23Q1' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InterestPaid' contextRef='Y22Q1' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt CG Times;margin:0;margin-left:10.1pt'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>3</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a8'></a><p style='font:10pt CG Times;margin:0'></p>
<table style='border-collapse:collapse;width:100%'><tr style='height:11.5pt'><td colspan='12' valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style='height:11.5pt'><td colspan='12' valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY FOR THE</span></p>
</td></tr>
<tr style='height:11.5pt'><td colspan='12' valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>THREE MONTHS ENDED MARCH 31, 2023 AND MARCH 31, 2022</span></p>
</td></tr>
<tr style='height:11.5pt'><td colspan='12' valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(in thousands - unaudited)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Accumulated</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Additional</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Other</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Total</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td colspan='3' valign='bottom' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Common Stock</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Paid-in</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Comprehensive</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Retained</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Stockholders'</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'></td><td valign='bottom' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Shares</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Amount</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Capital</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Income</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Earnings</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Equity</p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'> Balance at December 31, 2022</p>
</td><td valign='middle' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E22_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,628</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E22_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E22_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>251</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E22_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,039</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E22_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>126,006</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>114,254</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee stock options for cash</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='Y23Q1_StEqComps-CommonStock' unitRef='Shares' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y23Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y23Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>21</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y23Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y23Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>21</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y23Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y23Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y23Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>50</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y23Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y23Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>50</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>549</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'> <ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>549</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y23Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y23Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y23Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y23Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y23Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,070</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,070</ix:nonFraction>)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,214</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,214</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'> Balance at March 31, 2023</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E23Q1_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,628</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E23Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E23Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>322</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E23Q1_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,491</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E23Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>129,150</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>118,018</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle'><p style='font:10pt CG Times;margin:0'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'> Balance at December 31, 2021</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E21_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,655</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E21_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E21_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>841</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E21_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,054</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E21_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>115,314</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E21' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>107,138</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee stock options for cash</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='Shares' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>19</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>19</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>43</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>43</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q1_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>506</ix:nonFraction>)</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'> (<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y22Q1' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>506</ix:nonFraction>)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,060</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,060</ix:nonFraction>)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,534</ix:nonFraction></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,534</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'> Balance at March 31, 2022</p>
</td><td valign='middle' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E22Q1_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,655</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E22Q1_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E22Q1_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>903</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E22Q1_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,560</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E22Q1_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>117,788</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>109,168</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='middle'><p style='font:10pt CG Times;margin:0'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='bottom'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>4</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a9'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</span></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>(unaudited)</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' contextRef='Y23Q1' escape='true'><p style='font:10pt Times New Roman;margin:0'>(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. (&quot;UTMD&quot; or &quot;the Company&quot;) annual report on Form 10-K for the year ended December 31, 2022. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
</ix:nonNumeric><p style='font:10pt CG Times;margin:0'>&#160;</p>
 <ix:nonNumeric name='us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' contextRef='Y23Q1' escape='true'><p style='font:10pt Times New Roman;margin:0'>(2) Recent Accounting Standards. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock' contextRef='Y23Q1' escape='true'><p style='font:10pt Times New Roman;margin:0;color:#000000'>The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.</p>
</ix:nonNumeric></ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:InventoryDisclosureTextBlock' contextRef='Y23Q1' escape='true'><p style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt'>(3) Inventories at March 31, 2023 and December 31, 2022 consisted of the following:</p>
<ix:nonNumeric name='us-gaap:ScheduleOfInventoryCurrentTableTextBlock' contextRef='Y23Q1' escape='true'><table style='margin:0 auto;border-collapse:collapse;width:100%'><tr><td valign='top'></td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'> March 31, 2023  </p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>December 31, 2022</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>Finished goods</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryFinishedGoodsNetOfReserves' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,935</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryFinishedGoodsNetOfReserves' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,896</ix:nonFraction></p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0'>Work-in-process</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryWorkInProcess' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,500</ix:nonFraction></p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryWorkInProcess' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,193</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>Raw materials</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryRawMaterials' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,505</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryRawMaterials' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,725</ix:nonFraction></p>
</td></tr>
<tr><td valign='top'><p style='font:10pt Times New Roman;margin:0'>Total</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,940</ix:nonFraction></p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$</p>
</td><td valign='top' style='border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E22' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,814</ix:nonFraction></p>
</td></tr>
</table>
</ix:nonNumeric></ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' contextRef='Y23Q1' escape='true'><p style='font:10pt Times New Roman;margin:0'>(4) Stock-Based Compensation. At March 31, 2023, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended March 31, 2023 and 2022, the Company recognized $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>50</ix:nonFraction> and $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>43</ix:nonFraction>, respectively, in stock based compensation cost.</p>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:ProductWarrantyDisclosureTextBlock' contextRef='Y23Q1' escape='true'><p style='font:10pt Times New Roman;margin:0'> (5) Warranty Reserve. &#160;&#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; </p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, <ix:nonFraction name='us-gaap:ProductWarrantyAccrual' contextRef='E22' unitRef='USD' decimals='INF' format='ixt-sec:numwordsen'><ix:nonFraction name='us-gaap:ProductWarrantyAccrual' contextRef='E23Q1' unitRef='USD' decimals='INF' format='ixt-sec:numwordsen'>no</ix:nonFraction></ix:nonFraction> warranty reserve was made at December 31, 2022 or March 31, 2023. </p>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
 <ix:nonNumeric name='us-gaap:RevenueRecognitionPolicyTextBlock' contextRef='Y23Q1' escape='true'><p style='font:10pt Times New Roman;margin:0'>(6) &#160;1Q 2023 global revenues (USD) by product category:</p>
<ix:nonNumeric name='fil:ScheduleOfRevenuesByProductCategoryTextBlock' contextRef='Y23Q1' escape='true'><table style='margin:0 auto;border-collapse:collapse;width:100%'><tr style='height:11.5pt'><td valign='top'></td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Domestic</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Outside US</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Total</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>Obstetrics</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_ProductOrService-Obstetrics_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>806</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_ProductOrService-Obstetrics_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>209</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_ProductOrService-Obstetrics' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,015</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top'><p style='font:10pt Times New Roman;margin:0'>Gynecology/Electrosurgery/Urology</p>
</td><td valign='top'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,520</ix:nonFraction></span></p>
</td><td valign='top'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,073</ix:nonFraction></span></p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_ProductOrService-GynecologyElectrosurgeryUrology' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,593</ix:nonFraction></span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_ProductOrService-Neonatal_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,385</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_ProductOrService-Neonatal_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>377</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_ProductOrService-Neonatal' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,762</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top'><p style='font:10pt Times New Roman;margin:0'>Blood Pressure Monitoring and Accessories</p>
</td><td valign='top'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='border-bottom:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,474</ix:nonFraction></span></p>
</td><td valign='top'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='border-bottom:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,676</ix:nonFraction></span></p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='border-bottom:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_ProductOrService-BloodPressureMonitoringAndAccessories' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,150</ix:nonFraction></span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt'><span style='font-family:Times New Roman'>Total</span></p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,185</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,335</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,520</ix:nonFraction></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</p>
</ix:nonNumeric></ix:nonNumeric><p style='font:12pt Times New Roman;margin:0'></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>5</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><ix:nonNumeric name='us-gaap:IntangibleAssetsDisclosureTextBlock' contextRef='Y23Q1' escape='true'><p style='font:10pt Times New Roman;margin:0'>(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie&#174; Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $<ix:nonFraction name='us-gaap:FinitelivedIntangibleAssetsAcquired1' contextRef='Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>21,000</ix:nonFraction> purchase price represents an identifiable intangible asset which is being straight-line amortized and recognized as part of G&amp;A expenses over the <ix:nonFraction name='fil:RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' contextRef='D230331_DistributionRightsAcquisition-CoopersurgicalInc' unitRef='Pure' decimals='INF' scale='0' format='ixt:numdotdecimal'>7</ix:nonFraction> month remaining life, as of the end of 1Q 2023, of the prior CSI agreement with Femcare.</p>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:EarningsPerShareTextBlock' contextRef='Y23Q1' escape='true'><p style='font:10pt Times New Roman;margin:0'>(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of first quarter 2023.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' contextRef='Y23Q1' escape='true'><p style='font:10pt Times New Roman;margin:0'> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>(<i>in thousands</i>)</p>
</td><td colspan='3' valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Three months ended</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td colspan='3' valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>March 31,</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'></td><td valign='middle' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2023</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2022</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'><b>Numerator</b></span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net income</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y23Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,214</ix:nonFraction></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y22Q1' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,534</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'><b>Denominator</b></span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Weighted average shares, basic</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y23Q1' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,628</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y22Q1' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,655</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Dilutive effect of stock options</p>
</td><td valign='middle' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='Y23Q1' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>8</ix:nonFraction></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='Y22Q1' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>10</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Diluted shares</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y23Q1' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,636</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y22Q1' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,665</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per share, basic</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ <ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y23Q1' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.16</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ <ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y22Q1' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.97</ix:nonFraction></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per share, diluted</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ <ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y23Q1' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.16</ix:nonFraction></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ <ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y22Q1' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.96</ix:nonFraction></p>
</td></tr>
</table>
<p style='font:12pt Times New Roman;margin:0'>&#160;</p>
</ix:nonNumeric></ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:SubsequentEventsTextBlock' contextRef='Y23Q1' escape='true'><p style='font:10pt Times New Roman;margin:0;color:#000000'>(9) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.</p>
</ix:nonNumeric><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>6</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a10'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 2.</b> &#160;<b>Management's Discussion and Analysis of Financial Condition and Results of Operations</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>General</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Utah Medical Products, Inc. (UTMD) manufactures and markets a well-established range of specialty medical devices. &#160;The Company&#8217;s Form 10-K Annual Report for the year ended December 31, 2022 provided a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. &#160;Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. &#160;Currency amounts in the report are in thousands, except per share amounts or where otherwise noted. &#160;Currencies in this report are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&#160;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&#160;or EUR = Euros. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Analysis of Results of Operations</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>a)</kbd><kbd style='margin-left:24.3pt'></kbd>Overview&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Income statement results in the first quarter (1Q) of 2023 compared to 1Q 2022 were as follows:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-0.9pt;text-align:right'><span style='border-bottom:1px solid #000000'>1Q 2023</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1Q 2022</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net Sales</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 12,520</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 12,323</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>+1.6%</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gross Profit</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7,843</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7,532</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>+4.1%</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating Income</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4,439</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4,522</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(1.9%)</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Income Before Tax</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,119</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4,530</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>+13.0%</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net Income </p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4,214</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,534</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>+19.2%</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per Share (diluted)</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 1.159</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 0.964</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>+20.2%</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Profit margins in 1Q 2023 compared to 1Q 2022 follow:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>1Q 2023 </p>
<p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>(JAN &#8211;&#160;MAR)</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>1Q 2022 </p>
<p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>(JAN &#8211;&#160;MAR)</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit Margin (Gross Profit/ sales):</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>62.6%</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>61.1%</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income Margin (Operating Income/ sales):</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>35.5%</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>36.7%</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>EBT Margin (Profits before Income Taxes/ sales):</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>40.9%</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>36.8%</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income Margin (Profit after Taxes/ sales):</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>33.7%</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>28.7%</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Domestic sales in 1Q 2023 were 10% lower, but sales outside the U.S. (OUS) were up 23% in USD terms compared to 1Q 2022. &#160;Using the same foreign currency exchange (FX) rates for sales not invoiced in USD, i.e. in &#8220;constant currency&#8221; terms, OUS sales were up 28%. Because 28% of consolidated USD sales were invoiced in foreign currencies, the change in FX rates for OUS sales did have an impact on period-to-period relative financial results. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 1Q 2023 and 1Q 2022 follow: &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>1Q 2023</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>1Q 2022</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>GBP</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.215</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.339</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(9.3%)</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EUR</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.078</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.126</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>(4.2%)</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUD</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.685</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.724</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>(5.3%)</span></p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CAD</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.739</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.789</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>(6.3%)</span></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The weighted-average negative impact on foreign currency sales was 5.9%, reducing reported USD sales by $223 relative to the same foreign currency sales in 1Q 2022. &#160;In constant currency terms, total consolidated 1Q 2023 sales were up $420 (+3.4%).</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Due mostly to better absorption of manufacturing overhead costs in Ireland and lower employee healthcare plan costs in the U.S., UTMD was able to increase its 1Q 2023 Gross Profit Margin (GPM), gross profits/sales, compared to 1Q 2022. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Consolidated OI in 1Q 2023 at $4,439 (35.5% of sales) was $84 lower than 1Q 2022 OI of $4,522 (36.7% of sales). &#160;Although UTMD&#8217;s 1Q 2023 Operating Income Margin (OIM) benefitted from higher sales, a higher GPM and a stronger USD which reduced OUS operating expenses in USD terms by $80, it suffered more from the $348 (2.8% of sales) higher litigation expenses compared to 1Q 2022. &#160;The $1,105 per quarter straight-line amortization of the $21,000 purchase price that UTMD paid CSI in early 2019 to acquire the remaining 4.75 years&#8217; exclusive U.S. Filshie distribution rights was 8.8% of 1Q 2023 sales compared to 9.0% of 1Q 2022 sales. The purchase price of CSI&#8217;s remaining exclusive distribution rights was recognized as an identifiable intangible asset (IIA) which will be fully amortized in October 2023. IIA amortization expense in total, including that remaining from the 2011 Femcare acquisition, which comprises a significant portion of General &amp; Administrative (G&amp;A) operating expenses, was 12.7% of 1Q 2023 consolidated sales compared to 13.3% of 1Q 2022 consolidated sales. In other words, UTMD&#8217;s OIM excluding IIA amortization and litigation expense was 51.4% in 1Q 2023 compared to 50.5% in 1Q 2022.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Income Before Tax (EBT) benefitted from much higher interest income on UTMD&#8217;s cash reserves. &#160;&#160;Non-operating income (NOI) in 1Q 2023, in which interest income is captured, was $681 compared to $8 in 1Q 2022. As a result of $589 higher EBT and a lower income tax provision rate due to a portion of NOI received from tax exempt interest, UTMD&#8217;s Net Income Margin (NIM) in 1Q 2023 at 33.7% was substantially higher than the 28.7% NIM in 1Q 2022. &#160;UTMD&#8217;s consolidated income tax provision rate in 1Q 2023 was 17.7% of EBT compared to 22.0% in 1Q 2022. The result was that 1Q 2023 NI was 19.2% higher, and 1Q 2023 Earnings Per Share were 20.2% higher, than in 1Q 2022.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s March 31, 2023 Balance Sheet, in the absence of debt, remained strong. &#160;Ending Cash and Investments were $80.9 million on March 31, 2023 compared to $75.1 million on December 31, 2022. Stockholders&#8217; Equity was up $3.8 million in the first three-month calendar period from December 31, 2022. &#160;FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2023 and the end of 1Q 2022 follow:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%;margin-left:-1.7pt'><tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>3-31-23</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>3-31-22</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>GBP</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.237</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.315</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>(6.0%)</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EUR</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.087</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.110</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>(2.0%)</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUD</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.670</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.750</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>(10.6%)</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CAD</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.739</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.801</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>(7.7%)</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>7</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>b)</kbd><kbd style='margin-left:24.3pt'></kbd>Revenues&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Terms of sale are established in advance of UTMD&#8217;s acceptance of customer orders. &#160;In the U.S., Ireland, UK, Canada, Australia and New Zealand, UTMD generally accepted orders directly from and shipped directly to end user clinical facilities, as well as third party medical/surgical distributors, under UTMD&#8217;s Standard Terms and Conditions (T&amp;C) of Sale during both 1Q 2023 and 1Q 2022. &#160;UTMD may have separate discounted pricing agreements with a specific clinical facility or group of affiliated facilities based on volume of purchases. &#160;Pricing agreements which are documented arrangements with clinical facilities, or groups of affiliated facilities, if applicable, are established in advance of orders accepted or shipments made. For existing customers, past actual shipment volumes typically determine the fixed price by part number for the next agreement period of one year. For new customers, the customer&#8217;s best estimate of volume is usually accepted by UTMD for determining the ensuing fixed prices for the agreement period. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements with clinical facilities based on volume of purchases disclosure is not inconsistent with UTMD&#8217;s disclosure that the selling price is fixed prior to the acceptance of a specific customer order. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Total consolidated 1Q 2023 UTMD revenues (sales) were $197 (+1.6%) higher than in 1Q 2022. Constant currency sales were $420 (+3.4%) higher. U.S. domestic sales were 10.0% lower and OUS sales were 22.9% higher despite an average 5.9% stronger USD. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Domestic sales in 1Q 2023 were $7,185 compared to $7,984 in 1Q 2022. &#160;The components of domestic sales include 1) &#8220;direct sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;Filshie device sales&#8221;, manufactured by Femcare and distributed in the U.S. by UTMD. </p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>1)</kbd><kbd style='margin-left:10.8pt'></kbd>Direct sales, representing 50% of total domestic sales, were $372 (9.3%) lower in 1Q 2023 than in 1Q 2022. &#160;This was due to continuing supply chain disruption, in particular independent sterilizer capacity constraints. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>2)</kbd><kbd style='margin-left:10.8pt'></kbd>OEM sales, representing 32% of total domestic sales, were $375 (14.0%) lower. U.S. sales to UTMD&#8217;s largest OEM customer which had grown rapidly in recent years were $391 lower in 1Q 2023 compared to 1Q 2022. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>3)</kbd><kbd style='margin-left:10.8pt'></kbd>Filshie device sales were $51 (3.9%) lower in 1Q 2023 compared to 1Q 2022. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>OUS sales in 1Q 2023 were $5,335 compared to $4,339 in 1Q 2022. OUS sales invoiced in GBP, EUR, AUD and CAD currencies were reduced $223 as a result of changes in FX rates resulting from an average 5.9% stronger USD. &#160;In other words, constant currency OUS sales were $5,558, which was 28.1% higher than in 1Q 2022. &#160;The foreign currency OUS sales in 1Q 2023 were $3,558, which was 67% of OUS sales and 28% of total consolidated sales. &#160;Foreign currency OUS sales in 1Q 2022 were $2,906, which was 67% of OUS sales and 24% of total consolidated sales. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The following table provides USD consolidated sales amounts divided into general product categories for total worldwide sales and the subset of OUS sales:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>WW revenues (USD) by product category:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1Q 2023</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>%</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1Q 2022</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>%</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Obstetrics</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 1,015</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 1,049</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>9</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/ Electrosurgery/ Urology</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,593</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>45</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>5,102</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>41</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,762</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>14</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,873</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>15</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Blood Pressure Monitoring and Accessories*</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>4,150</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>33</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>4,299</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>35</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt'>Total:</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 12,520</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>100</span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 12,323</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>100</span></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>OUS revenues (USD) by product category:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1Q 2023</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>%</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1Q 2022</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>%</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Obstetrics</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 209</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 126</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/ Electrosurgery/ Urology</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,073</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>58</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,522</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>58</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>377</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>291</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Blood Pressure Monitoring and Accessories*</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1,676</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>31</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1,400</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>32</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:-19.8pt;margin-left:19.8pt'>Total:</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 5,335</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>100</span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 4,339</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>100</span></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:37.8pt'></kbd>*includes molded components sold to OEM customers.&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>8</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>c)</kbd><kbd style='margin-left:24.3pt'></kbd>Gross Profit&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Gross Profit results from subtracting the costs of manufacturing products, including quality assurance and freight for receiving raw materials from vendors, from revenues. UTMD&#8217;s Gross Profit was $310 (+4.1%) higher in 1Q 2023 than in 1Q 2022. &#160;Gross Profit increased more than revenues due primarily to two favorable period-to-period differences: better absorption of manufacturing overhead costs in Ireland as a result of production which increased more than overhead costs increased, and 2) much lower healthcare costs for U.S. employees compared to 1Q 2022 under UTMD&#8217;s self-funded plan. The Company selectively raised product prices during 1Q 2023 based on specific input costs from vendors. As another cost-of-living pay adjustment for employees becomes effective in April 2023, the Company still expects to maintain its GPM for the year as a whole consistent with 2022. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>d)</kbd><kbd style='margin-left:24.3pt'></kbd>Operating Income &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Operating Income results from subtracting Operating Expenses from Gross Profit. Operating Expenses are comprised of G&amp;A (G&amp;A) expenses, sales and marketing (S&amp;M) expenses and product development (R&amp;D) expenses. Consolidated Operating Expenses were $3,404 in 1Q 2023 (27.2% of sales) compared to $3,010 in 1Q 2022 (24.4% of sales). &#160;Ignoring the portion of Operating Expenses that were litigation expenses and non-cash IIA amortization expenses, consolidated Operating Expenses in 1Q 2023 were 11.2% of consolidated sales compared to 10.6% of sales in 1Q 2022. &#160;A stronger USD in 1Q 2023 compared to 1Q 2022 helped Operating Income performance by reducing OUS Operating Expenses in USD terms by $80, comprised of reducing IIA amortization expense by $49 and all other OUS Operating Expenses by $31. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Consolidated G&amp;A expenses were $2,873 (22.9% of sales) in 1Q 2023 compared to $2,551 (20.7% of sales) in 1Q 2022. G&amp;A expenses include litigation costs which were $409 in 1Q 2023 compared to $61 in 1Q 2022. The G&amp;A expenses in 1Q 2023 included $483 (3.9% of sales) of non-cash expense from the amortization of IIA resulting from the 2011 Femcare acquisition, which were $532 (4.3% of sales) in 1Q 2022. &#160;The lower USD IIA amortization expense was the result of a stronger USD, as the Femcare amortization expense in GBP in 1Q 2023 was the same as in 1Q 2022. In addition, G&amp;A expenses in both periods included $1,105 IIA amortization expense resulting from the purchase of the CSI remaining U.S. exclusive Filshie distribution rights, which represented 8.8% of 1Q 2023 sales compared to 9.0% of 1Q 2022 sales. &#160;Excluding the litigation and non-cash IIA amortization expenses, G&amp;A expenses were $876 (7.0% of sales) in 1Q 2023 compared to $853 (6.9% of sales) in 1Q 2022. &#160;The change in FX rates reduced 1Q 2023 OUS G&amp;A expenses by $74, comprised of reducing IIA amortization expense by $49 and all other G&amp;A expenses by $24.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>S&amp;M expenses were $387 (3.1% of sales) in 1Q 2023 compared to $336 (2.7% of sales) in 1Q 2022. &#160;The change in FX rates reduced 1Q 2023 OUS S&amp;M expenses by $6. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>R&amp;D expenses in 1Q 2023 were $144 (1.1% of sales) compared to $123 (1.0% of sales) in 1Q 2022. &#160;The change in FX rates reduced 1Q 2023 OUS R&amp;D expenses by $1.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>In summary, Operating Income in 1Q 2023 was $4,439 (35.5% of sales) compared to $4,522 (36.7% of sales) in 1Q 2022. &#160;The lower Operating Income Margin was due primarily to the $348 higher litigation expenses. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>A summary comparison of (USD) consolidated Operating Expenses follows:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1Q 2023</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1Q 2022</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>S&amp;M Expense</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;387</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;336</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>R&amp;D Expense</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>144</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>123</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>G&amp;A Expense:</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> &#160;&#160;&#160;&#160;CSI IIA amortization</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,105</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,105</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> &#160;&#160;&#160;&#160;Femcare IIA amortization</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>483</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>532</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> &#160;&#160;&#160;&#160;Litigation Expense</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>409</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>61</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> &#160;&#160;&#160;&#160;All Other G&amp;A Expenses</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>876</span></p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>853</span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total Operating Expenses:</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 3,404</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 3,010</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>After adjustment of OUS Operating Expenses for a stronger USD, the increases in S&amp;M, R&amp;D and All Other G&amp;A expenses (excluding litigation and IIA amortization) were essentially due to cost-of-living increases for employees.</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>9</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>e)</kbd><kbd style='margin-left:24.3pt'></kbd>Non-operating expense/ Non-operating income&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Net non-operating expense, or net non-operating income, results from the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income, royalties received from licensing the Company&#8217;s technology and other miscellaneous income. &#160;Net non-operating income in 1Q 2023 was $681 compared to $8 in 1Q 2022. &#160;The primary difference was due to higher average cash balances in 1Q 2023 compared to 1Q 2022 with higher interest rates, which resulted in $646 higher interest income. UTMD also received $9 higher non-operating income in 1Q 2023 from renting underutilized property compared to 1Q 2022, and the same non-operating income from royalties. UTMD realized a slight gain in 1Q 2023 compared to a loss of $3 at the end of 1Q 2022 from remeasurement of foreign currency bank balances. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>f)</kbd><kbd style='margin-left:24.3pt'></kbd>Income Before Income Taxes (EBT)&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>EBT results from adding net non-operating income to Operating Income. Consolidated 1Q 2023 EBT was $5,119 (40.9% of sales) compared to $4,530 (36.8% of sales) in 1Q 2022. The $589 (+13.0%) higher 1Q 2023 EBT compared to 1Q 2022 was the result of $673 higher non-operating income. In other words, the $646 higher interest income more than offset UTMD&#8217;s $348 higher litigation expenses. &#160;&#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The EBT of Utah Medical Products, Inc. in the U.S. was $2,562 in 1Q 2023 compared to $2,916 in 1Q 2022. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 1,962 in 1Q 2023 compared to EUR 1,806 in 1Q 2022. The EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP 23 in 1Q 2023 compared to GBP (159) in 1Q 2022. The 1Q 2023 EBT of Utah Medical Products Canada, Inc. was CAD 158 in 1Q 2023 compared to CAD 154 in 1Q 2022.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. &#160;Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 1Q 2023 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (&#8220;adjusted consolidated EBITDA&#8221;) were $6,919 compared to $6,371 in 1Q 2022, an 8.6% increase. Management believes that the 1Q 2023 EBITDA operating performance provides a start that is consistent with achieving its financial objectives for the calendar year 2023, as previously provided in its 2022 SEC 10-K Report. UTMD&#8217;s trailing last twelve-month EBITDA was $28,439. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number: &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1Q 2023</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>1Q 2022</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EBT</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;5,119</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;4,530</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Depreciation Expense</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>154</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>149</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Femcare IIA Amortization Expense</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>483</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>532</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CSI IIA Amortization Expense</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,105</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,105</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other Non-Cash Amortization Expense</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>8</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>9</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Stock Option Compensation Expense</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>50</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>43</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Interest Expense</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>-</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>-</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>Remeasured Foreign Currency Balances</p>
</td><td valign='top' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>-</p>
</td><td valign='top' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>UTMD non-US GAAP EBITDA:</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$  6,919</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$  6,371</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>10</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>g)</kbd><kbd style='margin-left:24.3pt'></kbd>Net Income&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Net Income in 1Q 2023 of $4,214 was 19.2% higher than the Net Income of $3,534 in 1Q 2022. UTMD&#8217;s Net Income Margin, Net Income divided by consolidated sales, was 33.7% in 1Q 2023 and 28.7% in 1Q 2022. The average consolidated income tax provision rates (as a % of EBT) in 1Q 2023 was 17.7% and in 1Q 2022 was 22.0%. The lower provision rate in 1Q 2023 resulted primarily from a portion of interest income that is tax-exempt. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:10.8pt'></kbd>h) &#160;Earnings Per Share (EPS)&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>EPS are consolidated Net Income divided by the weighted average number of shares of stock outstanding (diluted to take into consideration stock option awards which are &#8220;in the money,&#8221; i.e., have exercise prices below the applicable period&#8217;s weighted average market value).</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Diluted EPS in 1Q 2023 were 20.2% higher than in 1Q 2022. &#160;UTMD&#8217;s increase in NI was leveraged for EPS as a result of 28,629 fewer diluted shares used to calculate EPS in 1Q 2023 compared to 1Q 2022. Diluted shares were 3,636,286 in 1Q 2023 compared to 3,664,915 in 1Q 2022. &#160;Outstanding shares were 3,628,067 at the end of 1Q 2023. The number of shares used for calculating EPS was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. &#160;The total number of outstanding unexercised employee and outside director options at March 31, 2023 was 66,883 at an average exercise price of $73.64, including shares awarded but not yet vested. &#160;This compares to 67,433 unexercised option shares at the end of 2022 at an average exercise price of $73.66/ share, including shares awarded but not vested. The difference was due to 300 employee option exercises and 250 cancellations during 1Q 2023. The number of shares added as a dilution factor in 1Q 2023 was 8,456 compared to 10,125 in 1Q 2022. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Outstanding shares at the end of 1Q 2023 were 3,628,067 compared to 3,627,767 at the end of calendar year 2022. The difference was due to 300 employee option exercises during 1Q 2023.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>There were no stock repurchases in 1Q 2023. &#160;During the last year since the end of 1Q 2022, UTMD repurchased 30,105 of its shares. &#160;No options were awarded in 1Q 2023. &#160;During the last year since the end of 1Q 2022, 20,600 options were awarded to 40 employees at an exercise price of $82.60.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD paid a $1,070 ($0.295/share) cash dividend to stockholders in 1Q 2023. UTMD did not pay a cash dividend to stockholders in 1Q 2022 because the special $7,309 ($2.00/share) dividend, which was declared in 4Q 2021, was paid in December before the end of the 2021 calendar year instead of in January 2022. &#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>During 1Q 2023 and 1Q 2022, UTMD did not repurchase its shares. In 2Q 2022, UTMD repurchased 30,105 shares at $82.88 per share. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD&#8217;s closing share price at the end of 1Q 2023 was $94.77, down 6% from the $100.53 closing price at the end of 2022. &#160;The closing share price at the end of 1Q 2022 was $89.86. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>i) </kbd><kbd style='margin-left:24.3pt'></kbd>Return on Equity (ROE)&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>ROE is the portion of Net Income retained by UTMD to internally finance its growth, divided by the average accumulated Stockholders&#8217; Equity for the applicable time period. Annualized ROE (before stockholder dividends) in 1Q 2023 was 15% and in 1Q 2022 was 13%. &#160;The higher ROE in 1Q 2023 was due to 19% higher Net Income divided by 7% higher average Stockholders&#8217; Equity. Targeting a high ROE of 20% remains a key financial target for UTMD management. &#160;ROE can be increased by increasing Net Income, and/or by reducing Stockholders&#8217; Equity by paying cash dividends to stockholders or by repurchasing shares. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Liquidity and Capital Resources</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>j)</kbd><kbd style='margin-left:24.3pt'></kbd>Cash flows&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $6,915 in 1Q 2023 compared to $5,046 in 1Q 2022. &#160;Net Income provided $680 more to cash in 1Q 2023 than in 1Q 2022. &#160;Other differences in cash provided during the two periods were a $2,350 higher source of cash from trade accounts receivable, a $141 lower reduction in deferred income taxes and a $135 difference with lower instead of higher prepaid expenses and other current assets, offset by a $886 higher use of cash for accounts payable, a $276 higher increase in inventories and a $247 lower increase in accrued expenses. &#160;&#160;&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>11</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>Capital expenditures for property and equipment (PP&amp;E) were $43 in 1Q 2023 compared to $237 in 1Q 2022. &#160;Depreciation of PP&amp;E was $155 in 1Q 2023 compared to $149 in 1Q 2022. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Cash dividends paid to stockholders in 1Q 2023 were $1,070 compared to zero in 1Q 2022 because the special $7,309 dividend declared in 4Q 2021 was paid in December 2021 instead of in January 2022. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>In 1Q 2023, UTMD received $21 and issued 300 shares of its stock upon the exercise of employee stock options. &#160;Option exercises in 1Q 2023 were at an average price of $69.83 per share. &#160;In comparison, in 1Q 2022 UTMD received $19 and issued 250 shares of its stock upon the exercise of employee stock options. &#160;Option exercises in 1Q 2022 were at an average price of $76.33 per share. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to meet the challenges of the current economic environment in achieving operating objectives, to maintain the capability to make opportunistic investments that will provide for growth in future profits and to continue to allocate capital in a way that will maximize stockholder value over time. During the remainder of 2023 the Company may utilize cash not needed to support normal operations in one or a combination of the following: 1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMD&#8217;s existing infrastructure. &#160;If there are no better strategic uses for UTMD&#8217;s cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>k)</kbd><kbd style='margin-left:24.3pt'></kbd>Assets and Liabilities&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s March 31, 2023 Balance Sheet, in the absence of debt, continued to strengthen.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>March 31, 2023 total consolidated assets increased $3,896 from December 31, 2022 to $127,770. The increase was due to a $5,860 increase in cash and a $17 increase in net fixed assets (property, plant and equipment), offset by a $667 decrease in current assets other than cash and $1,314 lower net intangible assets. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The increase in cash was due to cash generated from operations coupled with a $781 decrease in non-cash working capital. Current assets as a whole increased $5,193 while current liabilities as a whole increased $114, yielding a $5,079 increase in working capital to $89,038. &#160;The decrease in current assets other than cash resulted primarily from a $1,720 decrease in receivables offset by an $1,126 increase in consolidated inventories. Average inventory turns were 2.0 in 1Q 2023 compared to 2.6 for the 2022 year. &#160;Accounts receivable were $1,720 lower due to faster collections, with the average age of trade receivables at 27 days from date of invoice at March 31, 2023 compared to 37 days at December 31, 2022. &#160;UTMD&#8217;s excellent 15.1 current ratio at December 31, 2022 improved to 15.7 at March 31, 2023 because current assets increased 5.8% when current liabilities increased just 1.9%. &#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The $17 higher net fixed assets at March 31, 2023 compared to December 31, 2022 resulted from $43 in capital expenditures, $155 in depreciation and the impact of the period-to-period foreign currency exchange (FX) rates for assets OUS. &#160;FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2023 and the end of 2022 follow:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%;margin-left:-1.7pt'><tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>&#160;</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>3-31-23</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>12-31-22</span></p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>GBP</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.237</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.208</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>+2.4%</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EUR</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.087</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.069</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>+1.7%</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUD</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.670</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.680</p>
</td><td valign='top' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>(1.5%)</p>
</td></tr>
<tr><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CAD</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.739</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.739</p>
</td><td valign='top' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>-</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>At March 31, 2023, net Intangible Assets decreased to 17.5% of total consolidated assets from 19.2% on December 31, 2022 because of the 1Q 2023 $1,588 amortization of identifiable intangibles, offset by a higher FX rate for remaining GBP intangible assets in the UK and aided by the higher period-end total asset denominator.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The $114 increase in current liabilities was a result of a $305 increase in accrued liabilities, primarily for income taxes and customer deposits, offset by a $191 decrease in accounts payable. Long term liabilities increased $19 to $3,678 primarily as a result of an increase in deferred income taxes in the U.S. and Ireland. Long term liabilities declined by a $57 lower deferred tax liability for the Femcare Ltd GBP IIA to $1,456 at March 31, 2023 compared to $9,084 on the date of the 2011 acquisition. Reduction of the deferred tax liability occurs as the book/tax difference of IIA amortization is eliminated over the remaining useful life of the Femcare Ltd IIA. UTMD&#8217;s total debt ratio (total liabilities/total assets) as of March 31, 2023 was 7.6% compared to 7.8% as of December 31, 2022.</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>12</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>l)</kbd><kbd style='margin-left:24.3pt'></kbd>Management's Outlook&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Based on the first quarter of 2023 results, UTMD expects to achieve its plan for 2023 as a whole, as described in its 2022 Form SEC 10-K. &#160;UTMD&#8217;s objectives for 2023 remain to</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:36pt'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:-18pt'>1)</kbd><kbd style='margin-left:-4.5pt'></kbd>exploit distribution and manufacturing synergies by further integrating capabilities and resources in its multinational operations; &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:36pt'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:-18pt'>2)</kbd><kbd style='margin-left:-4.5pt'></kbd>more effectively market the benefits of the Filshie Clip System in the U.S.;&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:36pt'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:-18pt'>3)</kbd><kbd style='margin-left:-4.5pt'></kbd>introduce additional products helpful to clinicians through internal new product development;&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:36pt'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:-18pt'>4)</kbd><kbd style='margin-left:-4.5pt'></kbd>continue to achieve profitable overall financial operating performance and a stable working environment for employees; &#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:36pt'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:-18pt'>5)</kbd><kbd style='margin-left:-4.5pt'></kbd>utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/when the UTMD share price seems undervalued; and&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:36pt'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:-18pt'>6)</kbd><kbd style='margin-left:-4.5pt'></kbd>be vigilant for accretive acquisition opportunities which may be brought about by the current challenging economic environment on companies with more limited resources. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>m)</kbd><kbd style='margin-left:24.3pt'></kbd>Accounting Policy Changes&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>None.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><b>Forward-Looking Information</b>. &#160;&#160;This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available. &#160;When used in this document, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221; and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. &#160;Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document. &#160;Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected, or intended. &#160;Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended. &#160;Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>13</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a11'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 3.</b> <b>Quantitative and Qualitative Disclosures about Market Risk</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP), in Australia denominated in the Australia Dollar (AUD), and in Canada denominated in the Canadian Dollar (CAD). &#160;The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD. &#160;The exchange rates were .9198, .9351 and .9013 EUR per USD as of March 31, 2023, December 31, 2022 and March 31, 2021, respectively. &#160;Exchange rates were .8085, .8280, and .7603 GBP per USD as of March 31, 2023, December 31, 2022 and March 31, 2022, respectively. &#160;Exchange rates were 1.4695, 1.4919 and 1.3338 AUD per USD on March 31, 2023, December 31, 2022 and March 31, 2022, respectively. &#160;Exchange rates were 1.3532, 1.3526, and 1.2571 CAD per USD on March 31, 2023, December 31, 2022, and March 31, 2022 respectively. UTMD manages its foreign currency risk without separate hedging transactions by either invoicing customers in the local currency where costs of production were incurred, by converting currencies as transactions occur, and by optimizing global account structures through liquidity management accounts.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a12'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 4. Controls and Procedures</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin-top:5pt;margin-bottom:5pt'>The Company&#8217;s management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of March 31, 2023. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of March 31, 2023, the Company&#8217;s disclosure controls and procedures were effective. </p>
<p style='font:10pt Times New Roman;margin:0'>There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the quarter ended March 31, 2023, that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal controls over financial reporting. </p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>14</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a13'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>PART II - OTHER INFORMATION</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a14'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 1. Legal Proceedings</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD is a party from time to time in litigation incidental to its business. Presently, except for the Filshie clip lawsuits initiated by a single U.S. law firm, there is no litigation or threatened litigation. The Company does not expect the outcome of the Filshie clip litigation will be material to consolidated financial results. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a15'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 1A. Risk Factors</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#333333'>In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in UTMD&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, which could materially affect its business, financial condition or future results. &#160;The risks described in the Annual Report on Form 10-K are not the only risks facing the Company. &#160;Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company&#8217;s business, financial condition and/or operating results.</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Legislative or executive order healthcare interference in the United States</span> renders the U.S. medical device marketplace unpredictable. A fully government-run healthcare system would likely eliminate healthcare consumer choice as well as commercial incentives for innovation. &#160;Restrictions on &#8220;nonessential&#8221; medical procedures during a pandemic reduce the demand for certain of UTMD&#8217;s medical devices.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Increasing regulatory burdens, including premarketing approval delays, may result in significant loss of revenue, unpredictable costs and loss of management focus on developing and marketing products that improve the quality of healthcare:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>Thousands of small focused medical device manufacturers including UTMD that do not have the overhead structure that the few large medical device companies can afford are increasingly burdened with bureaucratic and underqualified regulator demands that are not reasonably related to assuring the safety or effectiveness of the devices that they provide. &#160;Premarketing submission administrative burdens, and substantial &#8220;user fees&#8221; or notified body review fees, represent a significant non-clinical and/or non-scientific barrier to new product introduction, resulting in lack of investment or delays to revenues from new or improved devices. &#160;The risks associated with such circumstances relate not only to substantial out-of-pocket costs, including potential litigation in millions of dollars, but also loss of business and a diversion of attention of key employees for an extended period of time from managing their normal responsibilities, particularly in new product development and routine quality assurance activities.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Group Purchasing Organizations (GPOs) in the U.S. add non-productive costs, weaken the Company&#8217;s marketing and sales efforts and cause lower revenues by restricting access:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>GPOs, theoretically acting as bargaining agents for member hospitals, but actually collecting revenues from the companies that they are negotiating with, have made a concerted effort to turn medical devices that convey special patient safety advantages and better health outcomes, like UTMD&#8217;s, into undifferentiated commodities. GPOs have been granted an antitrust exemption by the U.S. Congress. Otherwise, their business model based on &#8220;kickbacks&#8221; would be a violation of law. &#160;Despite rhetoric otherwise, these bureaucratic entities do not recognize or understand the overall cost of care as it relates to safety and effectiveness of devices, and they create a substantial administrative burden that is primarily driven by collection of their administrative fees.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>The Company&#8217;s business strategy may not be successful in the future:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:8.55pt'></kbd>As the level of complexity and uncertainty in the medical device industry increases, evidenced, for example, by the unpredictable and overly cumbersome regulatory environment, the Company&#8217;s views of the future and product/ market strategy may not yield financial results consistent with the past.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>As the healthcare industry becomes increasingly bureaucratic it puts smaller companies like UTMD at a competitive disadvantage:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>An aging population is placing greater burdens on healthcare systems, particularly hospitals. The length of time and number of administrative steps required in adopting new products for use in hospitals has grown substantially in recent years. &#160;Smaller companies like UTMD typically do not have the administrative resources to deal with broad new administrative requirements, resulting in either loss of revenue or increased costs. &#160;As UTMD introduces new products it believes are safer and more effective, it may find itself excluded from certain clinical users because of the existence of long term supply agreements for preexisting products, particularly from competitors which offer hospitals a broader range of products and services. &#160;Restrictions used by hospital administrators to limit clinician involvement in device purchasing decisions makes communicating UTMD&#8217;s clinical advantages more difficult.&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>15</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>A product liability lawsuit could result in significant legal expenses and a large award against the Company:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>UTMD&#8217;s devices are frequently used in inherently risky situations to help physicians achieve a more positive outcome than what might otherwise be the case. &#160;In any lawsuit where an individual plaintiff suffered permanent physical injury, the possibility of a large award for damages exists whether or not a causal relationship exists.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>The Company&#8217;s reliance on third party distributors in some markets may result in less predictable revenues:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>UTMD&#8217;s distributors have varying expertise in marketing and selling specialty medical devices. &#160;They also sell other devices that may result in less focus on the Company&#8217;s products. &#160;In some countries, notably China, Pakistan and India not subject to similarly rigorous standards, a distributor of UTMD&#8217;s products may eventually become a competitor with a cheaper but lower quality version of UTMD&#8217;s devices.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>The loss of one or more key employees could negatively affect UTMD performance:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>In a small company with limited resources, the distraction or loss of key personnel at any point in time may be disruptive to performance. &#160;The Company&#8217;s benefits programs are key to recruiting and retaining talented employees. &#160;An increase in UTMD&#8217;s employee healthcare plan costs, for example, may cause the Company to have to reduce coverages which in turn represents a risk to retaining key employees.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Fluctuations in foreign currencies relative to the USD can result in significant differences in period-to-period financial results:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>Since a significant portion of UTMD&#8217;s sales are invoiced in foreign currencies and consolidated financial results are reported in USD terms, a stronger USD can have negative revenue effects. Conversely, a weaker USD would increase foreign subsidiary operating costs in USD terms. For the portion of sales to foreign entities made in fixed USD terms, a stronger USD makes the devices more expensive and weakens demand. &#160;For the portion invoiced in a foreign currency, not only USD-denominated sales are reduced, but also gross profits may be reduced because finished distributed devices and/or U.S. made raw materials and components are likely being purchased in fixed USD.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Trade restrictions and /or tariffs resulting from changing government trade policies have the potential to disrupt UTMD&#8217;s supply chain.</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Lack of predictability of a major OEM customer currently representing over 20% of UTMD&#8217;s sales.</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a16'></a><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'><b>Item 2.</b></kbd><kbd style='margin-left:37.8pt'></kbd><b>Unregistered Sales of Equity Securities and Use of Proceeds</b>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD did not purchase any of its own securities during 1Q 2023 and in 2022 it purchased 30,105 of its shares in the open market for $2,495 including commissions and fees ($82.88/ share.)</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a17'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 6. &#160;Exhibits </b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:11.5pt'><td valign='bottom'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Exhibit #</span></p>
</td><td valign='bottom'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Title of Document</span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>31.1</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex31z1.htm' style='text-decoration:none'>Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>31.2</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex31z2.htm' style='text-decoration:none'>Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>32.1</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex32z1.htm' style='text-decoration:none'>Certification of CEO pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>32.2</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex32z2.htm' style='text-decoration:none'>Certification of Principal Financial Officer pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></p>
</td></tr>
<tr style='height:11.5pt'><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>101</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>The following financial information from the Utah Medical Products, Inc. quarterly report on Form 10-Q for the quarter ended March 31, 2023, formatted in Inline Extensible Business Reporting Language (iXBRL): &#160;(i) Consolidated Condensed Balance Sheets, (ii) Consolidated Condensed Statements of Income, (iii) Consolidated Condensed Statements of Cash Flows, (iv) Consolidated Condensed Statements of Stockholders&#8217; Equity, and (v) related Notes to the Consolidated Condensed Financial Statements, tagged in detail.</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0;text-align:center'>104</p>
</td><td valign='top' style='background-color:#CCEEFF'><p style='font:10pt Times New Roman;margin:0'>Cover Page Interactive Data File (embedded within the Inline XBRL document)</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>16</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#0000FF;border-bottom:1px solid #0000FF'><a href='#a2' style='text-decoration:none'>Table of Contents</a></span></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a18'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>SIGNATURES</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:28.8pt'></kbd>Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:204.2pt'></kbd><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:204.2pt'></kbd>REGISTRANT&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>Date: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;5/5/23 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style='margin-left:204.2pt'></kbd>By: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Kevin L. Cornwell &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:55.4pt'> &#160;&#160;&#160;&#160;</kbd><kbd style='margin-left:219.1pt'></kbd>Kevin L. Cornwell&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:55.4pt'> &#160;&#160;&#160;&#160;</kbd><kbd style='margin-left:219.1pt'></kbd>CEO&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>Date: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;5/5/23 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style='margin-left:204.2pt'></kbd>By: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Brian L. Koopman &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:55.4pt'> &#160;&#160;&#160;&#160;</kbd><kbd style='margin-left:219.1pt'></kbd>Brian L. Koopman&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:219.1pt'></kbd>Principal Financial Officer&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>17</span></p>
<p style='font:10pt CG Times;margin:0'>&#160;</p>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>utmd_ex31z1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVD9NVDXT]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'><B>Exhibit 31.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF CEO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Kevin L. Cornwell, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: May 5, 2023</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt CG Times;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>utmd_ex31z2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVD9NVDXT]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 31.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Brian L. Koopman, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-15.3pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: May 5, 2023</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Brian L. Koopman</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>utmd_ex32z1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVD9NVDXT]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 32.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt Times New Roman;margin:0'>May 5, 2023</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt CG Times;margin:0'><FONT style='font-family:Times New Roman'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></FONT></P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>utmd_ex32z2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVD9NVDXT]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit 32.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Brian L. Koopman, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;/s/ Brian L. Koopman</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
<P style='font:10pt Times New Roman;margin:0'>May 5, 2023</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt CG Times;margin:0'><FONT style='font-family:Times New Roman'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon </I><I>request.</I></FONT></P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>utmd-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVD9NVDXT]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20230331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_Goodwill' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OtherLiabilitiesNoncurrent' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OperatingLeaseLiabilityNoncurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_Liabilities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_StockholdersEquity' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_CommonStockValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_GrossProfit' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_OperatingExpenses' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='2.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_Depreciation' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivable' use='optional' order='8.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='9.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='10.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='11.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='12.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='2.0' weight='-1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0' weight='1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>utmd-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVD9NVDXT]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20230331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquity' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureBasisOfPresentation" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureBasisOfPresentation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureBasisOfPresentation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureInventories" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureInventories"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureInventories"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureStockBasedCompensation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserve" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureWarrantyReserve"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserve"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognition" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureRevenueRecognition"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognition"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShare" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureEarningsPerShare"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShare"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureSubsequentEvents" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureSubsequentEvents"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureSubsequentEvents"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureStockBasedCompensationDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensationDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserveDetails" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureWarrantyReserveDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserveDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_DomesticUsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_OutsideUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_ObstetricsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_NeonatalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='fil_DistributionRightsAcquisitionAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='fil_DistributionRightsAcquisitionDomain' xlink:to='fil_CoopersurgicalIncMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FinitelivedIntangibleAssetsAcquired1' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' use='optional' order='2.0'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>utmd-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVD9NVDXT]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20230331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxesPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxesPaid' xlink:to='lab_us-gaap_IncomeTaxesPaid'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total adjustments</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total adjustments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Adjustments to reconcile net income to net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementLineItems' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement [Line Items]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementLineItems' xlink:to='lab_us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other comprehensive income (loss)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesOutstanding' xlink:to='lab_us-gaap_CommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherLiabilitiesNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other long term liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherLiabilitiesNoncurrent' xlink:to='lab_us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='lab_us-gaap_AssetsCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CoopersurgicalIncMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CooperSurgical Inc</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CoopersurgicalIncMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the CooperSurgical Inc, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CoopersurgicalIncMember' xlink:to='lab_fil_CoopersurgicalIncMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductOrServiceAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductOrServiceAxis' xlink:to='lab_srt_ProductOrServiceAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_StatementGeographicalAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_StatementGeographicalAxis' xlink:to='lab_srt_StatementGeographicalAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWorkInProcess' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Work-in-process</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWorkInProcess' xlink:to='lab_us-gaap_InventoryWorkInProcess'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:label='fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule Of Revenues By Product Category</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:to='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from issuance of common stock - options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:to='lab_us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInInventories' xlink:to='lab_us-gaap_IncreaseDecreaseInInventories'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementTable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementTable' xlink:to='lab_us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfGoodsAndServicesSold' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of goods sold</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfGoodsAndServicesSold' xlink:to='lab_us-gaap_CostOfGoodsAndServicesSold'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Security Exchange Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>OutsideUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the OutsideUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutsideUsMember' xlink:to='lab_fil_OutsideUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProvisionForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for losses on accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProvisionForDoubtfulAccounts' xlink:to='lab_us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AmortizationOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AmortizationOfIntangibleAssets' xlink:to='lab_us-gaap_AmortizationOfIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Comprehensive Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeMember' xlink:to='lab_us-gaap_ComprehensiveIncomeMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Diluted shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Shares outstanding (diluted)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:to='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for interest</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPaid' xlink:to='lab_us-gaap_InterestPaid'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (basic)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasic' xlink:to='lab_us-gaap_EarningsPerShareBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Operating income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='lab_us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross profit</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GrossProfit' xlink:to='lab_us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax liability - Femcare IIA</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:to='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsGross' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentTransitionReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Transition Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentTransitionReport' xlink:to='lab_dei_DocumentTransitionReport'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Remaining months of exclusive U.S. distribution rights for Femcare&apos;s Filshie Clip System</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Remaining months of exclusive U.S. distribution rights for Femcare&apos;s Filshie Clip System, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:to='lab_fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Neonatal</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Neonatal, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NeonatalMember' xlink:to='lab_fil_NeonatalMember'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Obstetrics</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Obstetrics, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ObstetricsMember' xlink:to='lab_fil_ObstetricsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Raw materials</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryRawMaterials' xlink:to='lab_us-gaap_InventoryRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PolicyTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Policies</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='lab_us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payment of dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Payment of dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsOfDividends' xlink:to='lab_us-gaap_PaymentsOfDividends'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ShareBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-based compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ShareBasedCompensation' xlink:to='lab_us-gaap_ShareBasedCompensation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfCashFlowsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='lab_us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DividendsCommonStockCash' xlink:to='lab_us-gaap_DividendsCommonStockCash'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementEquityComponentsAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Components [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='lab_us-gaap_StatementEquityComponentsAxis'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfFinancialPositionAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='lab_us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Blood Pressure Monitoring and Accessories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BloodPressureMonitoringAndAccessoriesMember' xlink:to='lab_fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:to='lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained Earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsMember' xlink:to='lab_us-gaap_RetainedEarningsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2023, 3,628 shares and December 31, 2022, 3,628 shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Goodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Goodwill</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Goodwill' xlink:to='lab_us-gaap_Goodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Tax Identification Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockOptionPlanExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock option compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockOptionPlanExpense' xlink:to='lab_us-gaap_StockOptionPlanExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Dilutive effect of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:to='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Warranty Reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyDisclosureTextBlock' xlink:to='lab_us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency translation adjustment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Foreign currency translation net of taxes of $0 in all periods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, diluted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (diluted)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareDiluted' xlink:to='lab_us-gaap_EarningsPerShareDiluted'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-Based Compensation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:to='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Cash at end of period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingGeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling, general and administrative</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingGeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Distribution Rights Acquisition</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionDomain' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Distribution Rights Acquisition, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DistributionRightsAcquisitionDomain' xlink:to='lab_fil_DistributionRightsAcquisitionDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finished goods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:to='lab_us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:to='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax benefit attributable to exercise of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:to='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SharesOutstanding' xlink:to='lab_us-gaap_SharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherNonoperatingIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherNonoperatingIncomeExpense' xlink:to='lab_us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='lab_us-gaap_OperatingExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares Authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesAuthorized' xlink:to='lab_us-gaap_CommonStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Earnings Per Share, Basic and Diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue Recognition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureTextBlock' xlink:to='lab_us-gaap_InventoryDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash provided by/(used in) financing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash provided by/(used in) financing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Depreciation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Depreciation' xlink:to='lab_us-gaap_Depreciation'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Sales, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:to='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='lab_us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNet' xlink:to='lab_us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash &amp; Investments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:to='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>DomesticUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the DomesticUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DomesticUsMember' xlink:to='lab_fil_DomesticUsMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense' xlink:label='us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AllocatedShareBasedCompensationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allocated Share-based Compensation Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AllocatedShareBasedCompensationExpense' xlink:to='lab_us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basis of Presentation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of exchange rate changes on cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityComponentDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Component</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityComponentDomain' xlink:to='lab_us-gaap_EquityComponentDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementOfStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='lab_us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research &amp; development</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpense' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpense'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Distribution Rights Acquisition [Axis]</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionAxis' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the description of Distribution Rights Acquisition, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='lab_fil_DistributionRightsAcquisitionAxis'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gynecology/Electrosurgery/Urology</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GynecologyElectrosurgeryUrologyMember' xlink:to='lab_fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrual' xlink:label='us-gaap_ProductWarrantyAccrual'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyAccrual' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Standard and Extended Product Warranty Accrual</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyAccrual' xlink:to='lab_us-gaap_ProductWarrantyAccrual'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TableTextBlockSupplementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tables/Schedules</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='lab_us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='lab_us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional Paid-in Capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalMember' xlink:to='lab_us-gaap_AdditionalPaidInCapitalMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_IncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesIssued' xlink:to='lab_us-gaap_CommonStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid-in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalCommonStock' xlink:to='lab_us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finite-Lived Intangible Assets Acquired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:to='lab_us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductsAndServicesDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductsAndServicesDomain' xlink:to='lab_srt_ProductsAndServicesDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SubsequentEventsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Subsequent Events</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SubsequentEventsTextBlock' xlink:to='lab_us-gaap_SubsequentEventsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock purchased and retired, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Weighted average shares, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Shares outstanding (basic)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:to='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Par or Stated Value Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareTextBlock' xlink:to='lab_us-gaap_EarningsPerShareTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:to='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:to='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Long-term lease liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:to='lab_us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentQuarterlyReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Quarterly Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentQuarterlyReport' xlink:to='lab_dei_DocumentQuarterlyReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_SegmentGeographicalDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_SegmentGeographicalDomain' xlink:to='lab_srt_SegmentGeographicalDomain'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Inventory, Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>New Accounting Pronouncements, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>New Accounting Pronouncements and Changes in Accounting Principles</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net increase in cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Changes in operating assets and liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProfitLoss' xlink:to='lab_us-gaap_ProfitLoss'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeStatementAbstract' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='lab_us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableCurrent' xlink:to='lab_us-gaap_AccountsPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherAssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='lab_us-gaap_OtherAssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CSI Distribution Agreement Purchase Disclosure</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:to='lab_us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockMember' xlink:to='lab_us-gaap_CommonStockMember'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='lab_us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expenses</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total operating expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='lab_us-gaap_StockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccruedLiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccruedLiabilitiesCurrent' xlink:to='lab_us-gaap_AccruedLiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsReceivableNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts &amp; other receivables, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsReceivableNetCurrent' xlink:to='lab_us-gaap_AccountsReceivableNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_Security12bTitle' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Title of 12(b) Security</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_Security12bTitle' xlink:to='lab_dei_Security12bTitle'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>utmd-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVD9NVDXT]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20230331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentQuarterlyReport' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentTransitionReport' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_Security12bTitle' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='33.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='34.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AssetsAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_Goodwill' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_Assets' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_OtherLiabilitiesNoncurrent' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_OperatingLeaseLiabilityNoncurrent' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='17.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='23.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='24.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract' xlink:label='us-gaap_StatementOfFinancialPositionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfFinancialPositionAbstract' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_GrossProfit' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='15.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='16.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_ComprehensiveIncomeNetOfTax' use='optional' order='19.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract' xlink:label='us-gaap_IncomeStatementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeStatementAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract' xlink:label='us-gaap_StatementOfStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfStockholdersEquityAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquity' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquity_1' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding_1' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract' xlink:label='us-gaap_StatementOfCashFlowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_Depreciation' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets' xlink:label='us-gaap_AmortizationOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_AmortizationOfIntangibleAssets' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' xlink:label='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivable' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='15.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='17.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='21.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='22.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' use='optional' order='24.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='25.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1' use='optional' order='26.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_IncomeTaxesPaid' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementOfCashFlowsAbstract' xlink:to='us-gaap_InterestPaid' use='optional' order='28.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureBasisOfPresentation" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureBasisOfPresentation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureBasisOfPresentation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureInventories" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureInventories"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureInventories">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_InventoryDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureStockBasedCompensation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserve" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureWarrantyReserve"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserve">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_ProductWarrantyDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognition" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureRevenueRecognition"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognition">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_RevenueRecognitionPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_IntangibleAssetsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShare" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureEarningsPerShare"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShare">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_EarningsPerShareTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureSubsequentEvents" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureSubsequentEvents"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureSubsequentEvents">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_SubsequentEventsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:label='fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='fil_ScheduleOfRevenuesByProductCategoryTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureStockBasedCompensationDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensationDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense' xlink:label='us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AllocatedShareBasedCompensationExpense' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserveDetails" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureWarrantyReserveDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserveDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductWarrantyAccrual' xlink:label='us-gaap_ProductWarrantyAccrual'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProductWarrantyAccrual' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_DomesticUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_OutsideUsMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_ObstetricsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_NeonatalMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='fil_DistributionRightsAcquisitionAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_CoopersurgicalIncMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FinitelivedIntangibleAssetsAcquired1' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20230331.xsd#fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" xlink:href="utmd-20230331.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='6.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>utmd-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK9NDL3JZWVD9NVDXT]. www.edgarsuite.com -->
<schema xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2023' xmlns:srt='http://fasb.org/srt/2023' xmlns:fil='http://www.utahmed.com/20230331' xmlns:dei='http://xbrl.sec.gov/dei/2023' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' targetNamespace='http://www.utahmed.com/20230331' xmlns:dtr-types='http://www.xbrl.org/dtr/type/2022-03-31' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xbrli='http://www.xbrl.org/2003/instance' elementFormDefault='qualified' attributeFormDefault='unqualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" id="idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
				<link:definition>000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" id="idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies">
				<link:definition>000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShare" id="idr_DisclosureEarningsPerShare">
				<link:definition>000150 - Disclosure - Earnings Per Share</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" id="idr_DisclosureInventoriesScheduleOfInventoryCurrentTables">
				<link:definition>000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureInventories" id="idr_DisclosureInventories">
				<link:definition>000100 - Disclosure - Inventories</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensationDetails" id="idr_DisclosureStockBasedCompensationDetails">
				<link:definition>000220 - Disclosure - Stock-Based Compensation (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserve" id="idr_DisclosureWarrantyReserve">
				<link:definition>000120 - Disclosure - Warranty Reserve</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognition" id="idr_DisclosureRevenueRecognition">
				<link:definition>000130 - Disclosure - Revenue Recognition</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow" id="idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow">
				<link:definition>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserveDetails" id="idr_DisclosureWarrantyReserveDetails">
				<link:definition>000230 - Disclosure - Warranty Reserve (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical">
				<link:definition>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure" id="idr_DisclosureCsiDistributionAgreementPurchaseDisclosure">
				<link:definition>000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical">
				<link:definition>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet" id="idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet">
				<link:definition>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails" id="idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails">
				<link:definition>000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" id="idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
				<link:definition>000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity">
				<link:definition>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensation" id="idr_DisclosureStockBasedCompensation">
				<link:definition>000110 - Disclosure - Stock-Based Compensation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureBasisOfPresentation" id="idr_DisclosureBasisOfPresentation">
				<link:definition>000080 - Disclosure - Basis of Presentation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" id="idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables">
				<link:definition>000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" id="idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples">
				<link:definition>000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" id="idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
				<link:definition>000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" id="idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables">
				<link:definition>000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome" id="idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome">
				<link:definition>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20230331/role/idr_DisclosureSubsequentEvents" id="idr_DisclosureSubsequentEvents">
				<link:definition>000160 - Disclosure - Subsequent Events</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2022-03-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2022-03-31'/>
	<import namespace='http://xbrl.sec.gov/dei/2023' schemaLocation='https://xbrl.sec.gov/dei/2023/dei-2023.xsd'/>
	<import namespace='http://fasb.org/us-gaap/2023' schemaLocation='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DomesticUsMember' name='DomesticUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OutsideUsMember' name='OutsideUsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ObstetricsMember' name='ObstetricsMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NeonatalMember' name='NeonatalMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_GynecologyElectrosurgeryUrologyMember' name='GynecologyElectrosurgeryUrologyMember'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BloodPressureMonitoringAndAccessoriesMember' name='BloodPressureMonitoringAndAccessoriesMember'/>
	<element nillable='true' type='dtr-types:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleOfRevenuesByProductCategoryTextBlock' name='ScheduleOfRevenuesByProductCategoryTextBlock'/>
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrldt:dimensionItem' xbrli:periodType='duration' id='fil_DistributionRightsAcquisitionAxis' name='DistributionRightsAcquisitionAxis'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DistributionRightsAcquisitionDomain' name='DistributionRightsAcquisitionDomain'/>
	<element abstract='true' nillable='true' type='dtr-types:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CoopersurgicalIncMember' name='CoopersurgicalIncMember'/>
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' name='RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711095901440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 04, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000706698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UTMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0342734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,628,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711095332192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Investments</a></td>
<td class="nump">$ 80,912<span></span>
</td>
<td class="nump">$ 75,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts &amp; other receivables, net</a></td>
<td class="nump">3,818<span></span>
</td>
<td class="nump">5,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">9,940<span></span>
</td>
<td class="nump">8,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">95,112<span></span>
</td>
<td class="nump">89,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,241<span></span>
</td>
<td class="nump">10,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,502<span></span>
</td>
<td class="nump">13,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangible assets</a></td>
<td class="nump">53,443<span></span>
</td>
<td class="nump">52,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Other intangible assets - accumulated amortization</a></td>
<td class="num">(44,528)<span></span>
</td>
<td class="num">(42,378)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">8,915<span></span>
</td>
<td class="nump">10,377<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">127,770<span></span>
</td>
<td class="nump">123,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,046<span></span>
</td>
<td class="nump">4,742<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,074<span></span>
</td>
<td class="nump">5,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred tax liability - Femcare IIA</a></td>
<td class="nump">1,456<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">638<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,752<span></span>
</td>
<td class="nump">9,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2023, 3,628 shares and December 31, 2022, 3,628 shares</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(11,490)<span></span>
</td>
<td class="num">(12,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">129,150<span></span>
</td>
<td class="nump">126,006<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">118,018<span></span>
</td>
<td class="nump">114,254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 127,770<span></span>
</td>
<td class="nump">$ 123,874<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711096134976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">3,628<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">3,628<span></span>
</td>
<td class="nump">3,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711095305456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 12,520<span></span>
</td>
<td class="nump">$ 12,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,677<span></span>
</td>
<td class="nump">4,790<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">7,843<span></span>
</td>
<td class="nump">7,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">3,260<span></span>
</td>
<td class="nump">2,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,404<span></span>
</td>
<td class="nump">3,011<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">4,439<span></span>
</td>
<td class="nump">4,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">5,119<span></span>
</td>
<td class="nump">4,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 4,214<span></span>
</td>
<td class="nump">$ 3,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per common share (basic)</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share (diluted)</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares outstanding (basic)</a></td>
<td class="nump">3,628<span></span>
</td>
<td class="nump">3,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares outstanding (diluted)</a></td>
<td class="nump">3,636<span></span>
</td>
<td class="nump">3,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation net of taxes of $0 in all periods</a></td>
<td class="nump">$ 549<span></span>
</td>
<td class="num">$ (506)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">$ 4,763<span></span>
</td>
<td class="nump">$ 3,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711095898528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711091328736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity Balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
<td class="num">$ (9,054)<span></span>
</td>
<td class="nump">$ 115,314<span></span>
</td>
<td class="nump">$ 107,138<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">3,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(506)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,534<span></span>
</td>
<td class="nump">3,534<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity Balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">903<span></span>
</td>
<td class="num">(9,560)<span></span>
</td>
<td class="nump">117,788<span></span>
</td>
<td class="nump">109,168<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2022</a></td>
<td class="nump">3,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity Balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="num">(12,039)<span></span>
</td>
<td class="nump">126,006<span></span>
</td>
<td class="nump">114,254<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">3,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,070)<span></span>
</td>
<td class="num">(1,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,214<span></span>
</td>
<td class="nump">4,214<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity Balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="num">$ (11,491)<span></span>
</td>
<td class="nump">$ 129,150<span></span>
</td>
<td class="nump">$ 118,018<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">3,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711097471920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 4,214<span></span>
</td>
<td class="nump">$ 3,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,596<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for losses on accounts receivable</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating Lease, Right-of-Use Asset, Amortization Expense</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised', window );">Tax benefit attributable to exercise of stock options</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable and other receivables</a></td>
<td class="nump">1,789<span></span>
</td>
<td class="num">(578)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(1,084)<span></span>
</td>
<td class="num">(809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(193)<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">2,701<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">6,915<span></span>
</td>
<td class="nump">5,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock - options</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividends</a></td>
<td class="num">(1,070)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by/(used in) financing activities</a></td>
<td class="num">(1,049)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">5,860<span></span>
</td>
<td class="nump">4,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">75,052<span></span>
</td>
<td class="nump">60,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">80,912<span></span>
</td>
<td class="nump">65,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxExpenseFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711100924992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2022. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711100471808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements and Changes in Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(2) Recent Accounting Standards. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711100471808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt">(3) Inventories at March 31, 2023 and December 31, 2022 consisted of the following:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td valign="top"/><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"> March 31, 2023  </p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2022</p>
</td></tr>
<tr><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,935</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,896</p>
</td></tr>
<tr><td valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,500</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,193</p>
</td></tr>
<tr><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,505</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,725</p>
</td></tr>
<tr><td valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,940</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,814</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711101963408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(4) Stock-Based Compensation. At March 31, 2023, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended March 31, 2023 and 2022, the Company recognized $50 and $43, respectively, in stock based compensation cost.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711100445952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warranty Reserve<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">Warranty Reserve</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"> (5) Warranty Reserve. &#160;&#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2022 or March 31, 2023. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711101964208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(6) &#160;1Q 2023 global revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td valign="top"/><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">806</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">209</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,015</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,520</span></p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">3,073</span></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">5,593</span></p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,385</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">377</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,762</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,474</span></p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">1,676</span></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">4,150</span></p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"><span style="font-family:Times New Roman">Total</span></p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,185</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,335</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">12,520</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711101907568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CSI Distribution Agreement Purchase Disclosure<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">CSI Distribution Agreement Purchase Disclosure</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie&#174; Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represents an identifiable intangible asset which is being straight-line amortized and recognized as part of G&amp;A expenses over the 7 month remaining life, as of the end of 1Q 2023, of the prior CSI agreement with Femcare.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711100389408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of first quarter 2023.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">(<i>in thousands</i>)</p>
</td><td colspan="3" style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">March 31,</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"/><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2022</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Numerator</b></span></p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,214</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,534</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Denominator</b></span></p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,628</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,655</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">8</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">10</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,636</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,665</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.16</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 0.97</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.16</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 0.96</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711097045536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(9) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711100452976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711100336368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories: Schedule of Inventory, Current (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td valign="top"/><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"> March 31, 2023  </p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2022</p>
</td></tr>
<tr><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,935</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,896</p>
</td></tr>
<tr><td valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,500</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,193</p>
</td></tr>
<tr><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,505</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,725</p>
</td></tr>
<tr><td valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">9,940</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$</p>
</td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">8,814</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711098125760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition: Schedule Of Revenues By Product Category (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_ScheduleOfRevenuesByProductCategoryTextBlock', window );">Schedule Of Revenues By Product Category</a></td>
<td class="text"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td valign="top"/><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">806</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">209</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,015</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,520</span></p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">3,073</span></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">5,593</span></p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,385</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">377</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,762</p>
</td></tr>
<tr style="height:11.5pt"><td valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,474</span></p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">1,676</span></p>
</td><td valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">4,150</span></p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"><span style="font-family:Times New Roman">Total</span></p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,185</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5,335</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">12,520</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfRevenuesByProductCategoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleOfRevenuesByProductCategoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711100394128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">(<i>in thousands</i>)</p>
</td><td colspan="3" style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">March 31,</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"/><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2023</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2022</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Numerator</b></span></p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,214</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,534</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><span style="border-bottom:1px solid #000000"><b>Denominator</b></span></p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,628</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,655</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">8</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">10</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,636</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,665</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:11.5pt"><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.16</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 0.97</p>
</td></tr>
<tr style="height:11.5pt"><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 1.16</p>
</td><td style="padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">$ 0.96</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711096050720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories: Schedule of Inventory, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 1,935<span></span>
</td>
<td class="nump">$ 1,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">6,505<span></span>
</td>
<td class="nump">5,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 9,940<span></span>
</td>
<td class="nump">$ 8,814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711100247984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711100420528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warranty Reserve (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Standard and Extended Product Warranty Accrual</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711098143904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition: Schedule Of Revenues By Product Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 12,520<span></span>
</td>
<td class="nump">$ 12,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_ObstetricsMember', window );">Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember', window );">Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_NeonatalMember', window );">Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember', window );">Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">4,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">7,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">3,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 1,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_ObstetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_ObstetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_NeonatalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_NeonatalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_DomesticUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_DomesticUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_OutsideUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_OutsideUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711100941024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CSI Distribution Agreement Purchase Disclosure (Details) - CooperSurgical Inc<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-Lived Intangible Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem', window );">Remaining months of exclusive U.S. distribution rights for Femcare's Filshie Clip System</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the Remaining months of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DistributionRightsAcquisitionAxis=fil_CoopersurgicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DistributionRightsAcquisitionAxis=fil_CoopersurgicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139711095383424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 4,214<span></span>
</td>
<td class="nump">$ 3,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, basic</a></td>
<td class="nump">3,628<span></span>
</td>
<td class="nump">3,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of stock options</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares</a></td>
<td class="nump">3,636<span></span>
</td>
<td class="nump">3,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>utmd-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:fil="http://www.utahmed.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20230331.xsd" xlink:type="simple"/>
    <context id="Y23Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="E23Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="I230504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="E22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Y22Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="E21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="E22Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Y23Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="E22_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E22_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E22_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E22_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="E23Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="E23Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="E23Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="E23Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="E21_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="E21_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="E21_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="E21_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Y22Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Y22Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Y22Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Y22Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="E22Q1_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="E22Q1_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="E22Q1_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="E22Q1_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Y23Q1_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y23Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fil:DistributionRightsAcquisitionAxis">fil:CoopersurgicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D230331_DistributionRightsAcquisition-CoopersurgicalInc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fil:DistributionRightsAcquisitionAxis">fil:CoopersurgicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="UsdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="Y23Q1" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="Y23Q1" id="fact2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="Y23Q1" id="fact3">Yes</dei:EntityCurrentReportingStatus>
    <dei:AmendmentFlag contextRef="Y23Q1" id="fact4">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="Y23Q1" id="fact5">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="Y23Q1" id="fact6">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="Y23Q1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="Y23Q1">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="Y23Q1">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="Y23Q1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="Y23Q1">001-12575</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="Y23Q1">UTAH MEDICAL PRODUCTS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="Y23Q1">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="Y23Q1">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="Y23Q1">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="Y23Q1">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="Y23Q1">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="Y23Q1">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="Y23Q1">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="Y23Q1">566-1200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="Y23Q1">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="Y23Q1">UTMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="Y23Q1">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityInteractiveDataCurrent contextRef="Y23Q1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="Y23Q1">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="Y23Q1">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="Y23Q1">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="Y23Q1">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="I230504" decimals="INF" unitRef="Shares">3628067</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E23Q1" decimals="-3" unitRef="USD">80912000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E22" decimals="-3" unitRef="USD">75052000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="E23Q1" decimals="-3" unitRef="USD">3818000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="E22" decimals="-3" unitRef="USD">5538000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="E23Q1" decimals="-3" unitRef="USD">9940000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E22" decimals="-3" unitRef="USD">8814000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="E23Q1" decimals="-3" unitRef="USD">442000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="E22" decimals="-3" unitRef="USD">515000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="E23Q1" decimals="-3" unitRef="USD">95112000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="E22" decimals="-3" unitRef="USD">89919000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="E23Q1" decimals="-3" unitRef="USD">10241000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="E22" decimals="-3" unitRef="USD">10224000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill contextRef="E23Q1" decimals="-3" unitRef="USD">13502000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="E22" decimals="-3" unitRef="USD">13354000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="E23Q1" decimals="-3" unitRef="USD">53443000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="E22" decimals="-3" unitRef="USD">52755000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="E23Q1" decimals="-3" unitRef="USD">44528000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="E22" decimals="-3" unitRef="USD">42378000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="E23Q1" decimals="-3" unitRef="USD">8915000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="E22" decimals="-3" unitRef="USD">10377000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets contextRef="E23Q1" decimals="-3" unitRef="USD">127770000</us-gaap:Assets>
    <us-gaap:Assets contextRef="E22" decimals="-3" unitRef="USD">123874000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="E23Q1" decimals="-3" unitRef="USD">1028000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="E22" decimals="-3" unitRef="USD">1218000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="E23Q1" decimals="-3" unitRef="USD">5046000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="E22" decimals="-3" unitRef="USD">4742000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="E23Q1" decimals="-3" unitRef="USD">6074000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="E22" decimals="-3" unitRef="USD">5960000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="E23Q1" decimals="-3" unitRef="USD">1456000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="E22" decimals="-3" unitRef="USD">1514000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="E23Q1" decimals="-3" unitRef="USD">1256000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="E22" decimals="-3" unitRef="USD">1256000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="E23Q1" decimals="-3" unitRef="USD">328000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="E22" decimals="-3" unitRef="USD">341000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="E23Q1" decimals="-3" unitRef="USD">638000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="E22" decimals="-3" unitRef="USD">549000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="E23Q1" decimals="-3" unitRef="USD">9752000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="E22" decimals="-3" unitRef="USD">9620000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="E23Q1" decimals="INF" unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="E22" decimals="INF" unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="E23Q1" decimals="-3" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="E22" decimals="-3" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="E23Q1" decimals="-3" unitRef="Shares">3628000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="E23Q1" decimals="-3" unitRef="Shares">3628000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="E22" decimals="-3" unitRef="Shares">3628000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="E22" decimals="-3" unitRef="Shares">3628000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="E23Q1" decimals="-3" unitRef="USD">36000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="E22" decimals="-3" unitRef="USD">36000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="E23Q1" decimals="-3" unitRef="USD">-11490000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="E22" decimals="-3" unitRef="USD">-12039000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="E23Q1" decimals="-3" unitRef="USD">322000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="E22" decimals="-3" unitRef="USD">251000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="E23Q1" decimals="-3" unitRef="USD">129150000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="E22" decimals="-3" unitRef="USD">126006000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="E23Q1" decimals="-3" unitRef="USD">118018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E22" decimals="-3" unitRef="USD">114254000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="E23Q1" decimals="-3" unitRef="USD">127770000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="E22" decimals="-3" unitRef="USD">123874000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Y23Q1" decimals="-3" unitRef="USD">12520000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Y22Q1" decimals="-3" unitRef="USD">12323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="Y23Q1" decimals="-3" unitRef="USD">4677000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="Y22Q1" decimals="-3" unitRef="USD">4790000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="Y23Q1" decimals="-3" unitRef="USD">7843000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="Y22Q1" decimals="-3" unitRef="USD">7533000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Y23Q1" decimals="-3" unitRef="USD">3260000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Y22Q1" decimals="-3" unitRef="USD">2888000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="Y23Q1" decimals="-3" unitRef="USD">144000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="Y22Q1" decimals="-3" unitRef="USD">123000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="Y23Q1" decimals="-3" unitRef="USD">3404000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="Y22Q1" decimals="-3" unitRef="USD">3011000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="Y23Q1" decimals="-3" unitRef="USD">4439000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="Y22Q1" decimals="-3" unitRef="USD">4522000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="Y23Q1" decimals="-3" unitRef="USD">680000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="Y22Q1" decimals="-3" unitRef="USD">8000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Y23Q1" decimals="-3" unitRef="USD">5119000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Y22Q1" decimals="-3" unitRef="USD">4530000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="Y23Q1" decimals="-3" unitRef="USD">905000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="Y22Q1" decimals="-3" unitRef="USD">996000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="Y23Q1" decimals="-3" unitRef="USD">4214000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y22Q1" decimals="-3" unitRef="USD">3534000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic contextRef="Y23Q1" decimals="INF" unitRef="UsdPerShare">1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="Y22Q1" decimals="INF" unitRef="UsdPerShare">0.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="Y23Q1" decimals="INF" unitRef="UsdPerShare">1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="Y22Q1" decimals="INF" unitRef="UsdPerShare">0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y23Q1" decimals="-3" unitRef="Shares">3628000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y22Q1" decimals="-3" unitRef="Shares">3655000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y23Q1" decimals="-3" unitRef="Shares">3636000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y22Q1" decimals="-3" unitRef="Shares">3665000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Y23Q1" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Y22Q1" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Y23Q1" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Y22Q1" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y23Q1" decimals="-3" unitRef="USD">549000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y22Q1" decimals="-3" unitRef="USD">-506000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Y23Q1" decimals="-3" unitRef="USD">4763000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Y22Q1" decimals="-3" unitRef="USD">3028000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss contextRef="Y23Q1" decimals="-3" unitRef="USD">4214000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y22Q1" decimals="-3" unitRef="USD">3534000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation contextRef="Y23Q1" decimals="-3" unitRef="USD">155000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="Y22Q1" decimals="-3" unitRef="USD">149000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="Y23Q1" decimals="-3" unitRef="USD">1596000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="Y22Q1" decimals="-3" unitRef="USD">1646000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="Y23Q1" decimals="-3" unitRef="USD">1000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="Y22Q1" decimals="-3" unitRef="USD">8000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="Y23Q1" decimals="-3" unitRef="USD">13000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="Y22Q1" decimals="-3" unitRef="USD">14000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="Y23Q1" decimals="-3" unitRef="USD">-3000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="Y22Q1" decimals="-3" unitRef="USD">-144000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation contextRef="Y23Q1" decimals="-3" unitRef="USD">50000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="Y22Q1" decimals="-3" unitRef="USD">43000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised contextRef="Y23Q1" decimals="-3" unitRef="USD">2000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised contextRef="Y22Q1" decimals="-3" unitRef="USD">0</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Y23Q1" decimals="-3" unitRef="USD">-1789000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Y22Q1" decimals="-3" unitRef="USD">578000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="Y23Q1" decimals="-3" unitRef="USD">1084000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="Y22Q1" decimals="-3" unitRef="USD">809000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Y23Q1" decimals="-3" unitRef="USD">-25000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Y22Q1" decimals="-3" unitRef="USD">109000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Y23Q1" decimals="-3" unitRef="USD">-193000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Y22Q1" decimals="-3" unitRef="USD">695000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Y23Q1" decimals="-3" unitRef="USD">350000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Y22Q1" decimals="-3" unitRef="USD">597000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="Y23Q1" decimals="-3" unitRef="USD">2701000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="Y22Q1" decimals="-3" unitRef="USD">1512000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Y23Q1" decimals="-3" unitRef="USD">6915000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Y22Q1" decimals="-3" unitRef="USD">5046000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Y23Q1" decimals="-3" unitRef="USD">43000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Y22Q1" decimals="-3" unitRef="USD">237000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Y23Q1" decimals="-3" unitRef="USD">-43000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Y22Q1" decimals="-3" unitRef="USD">-237000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Y23Q1" decimals="-3" unitRef="USD">21000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Y22Q1" decimals="-3" unitRef="USD">19000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfDividends contextRef="Y23Q1" decimals="-3" unitRef="USD">1070000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="Y22Q1" decimals="-3" unitRef="USD">0</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Y23Q1" decimals="-3" unitRef="USD">-1049000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Y22Q1" decimals="-3" unitRef="USD">19000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Y23Q1" decimals="-3" unitRef="USD">37000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Y22Q1" decimals="-3" unitRef="USD">71000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Y23Q1" decimals="-3" unitRef="USD">5860000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Y22Q1" decimals="-3" unitRef="USD">4899000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E22" decimals="-3" unitRef="USD">75052000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E21" decimals="-3" unitRef="USD">60974000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E23Q1" decimals="-3" unitRef="USD">80912000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="E22Q1" decimals="-3" unitRef="USD">65873000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="Y23Q1" decimals="-3" unitRef="USD">129000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="Y22Q1" decimals="-3" unitRef="USD">82000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaid contextRef="Y23Q1" decimals="-3" unitRef="USD">0</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="Y22Q1" decimals="-3" unitRef="USD">0</us-gaap:InterestPaid>
    <us-gaap:SharesOutstanding
      contextRef="E22_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3628000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="E22_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E22_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">251000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E22_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-12039000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E22_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">126006000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E22" decimals="-3" unitRef="USD">114254000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Y23Q1" decimals="-3" unitRef="USD">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">50000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="Y23Q1" decimals="-3" unitRef="USD">50000</us-gaap:StockOptionPlanExpense>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">549000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y23Q1" decimals="-3" unitRef="USD">549000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">1070000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="Y23Q1" decimals="-3" unitRef="USD">1070000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">4214000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y23Q1" decimals="-3" unitRef="USD">4214000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E23Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3628000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="E23Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E23Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E23Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-11491000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E23Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">129150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E23Q1" decimals="-3" unitRef="USD">118018000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="E21_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3655000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="E21_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E21_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">841000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E21_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-9054000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E21_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">115314000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E21" decimals="-3" unitRef="USD">107138000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y22Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Y22Q1" decimals="-3" unitRef="USD">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">43000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y22Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="Y22Q1" decimals="-3" unitRef="USD">43000</us-gaap:StockOptionPlanExpense>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-506000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y22Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y22Q1" decimals="-3" unitRef="USD">-506000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y22Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">1060000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="Y22Q1" decimals="-3" unitRef="USD">1060000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y22Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">3534000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y22Q1" decimals="-3" unitRef="USD">3534000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3655000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="E22Q1_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E22Q1_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">903000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E22Q1_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-9560000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="E22Q1_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">117788000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E22Q1" decimals="-3" unitRef="USD">109168000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Y23Q1">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2022. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.&lt;/p&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="Y23Q1">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(2) Recent Accounting Standards. &lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Y23Q1">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="Y23Q1">&lt;p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt"&gt;(3) Inventories at March 31, 2023 and December 31, 2022 consisted of the following:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td valign="top"/&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt; March 31, 2023  &lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31, 2022&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,935&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,896&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,500&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,193&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,505&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,725&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,940&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8,814&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Y23Q1">&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td valign="top"/&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt; March 31, 2023  &lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31, 2022&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,935&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,896&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,500&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,193&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,505&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,725&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;9,940&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8,814&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="E23Q1" decimals="-3" unitRef="USD">1935000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="E22" decimals="-3" unitRef="USD">1896000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcess contextRef="E23Q1" decimals="-3" unitRef="USD">1500000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="E22" decimals="-3" unitRef="USD">1193000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials contextRef="E23Q1" decimals="-3" unitRef="USD">6505000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="E22" decimals="-3" unitRef="USD">5725000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryNet contextRef="E23Q1" decimals="-3" unitRef="USD">9940000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E22" decimals="-3" unitRef="USD">8814000</us-gaap:InventoryNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Y23Q1">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(4) Stock-Based Compensation. At March 31, 2023, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt;. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended March 31, 2023 and 2022, the Company recognized $50 and $43, respectively, in stock based compensation cost.&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Y23Q1" decimals="-3" unitRef="USD">50000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Y22Q1" decimals="-3" unitRef="USD">43000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProductWarrantyDisclosureTextBlock contextRef="Y23Q1">&lt;p style="font:10pt Times New Roman;margin:0"&gt; (5) Warranty Reserve. &#160;&#160;The Company&#x2019;s published warranty is: &#x201c;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#x201d; &lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"&gt;UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2022 or March 31, 2023. &lt;/p&gt;
</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:ProductWarrantyAccrual contextRef="E22" decimals="INF" unitRef="USD">0</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="E23Q1" decimals="INF" unitRef="USD">0</us-gaap:ProductWarrantyAccrual>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Y23Q1">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(6) &#160;1Q 2023 global revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr style="height:11.5pt"&gt;&lt;td valign="top"/&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;806&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;209&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,015&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,520&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;3,073&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;5,593&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,385&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;377&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,762&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,474&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;1,676&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;4,150&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;&lt;span style="font-family:Times New Roman"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,185&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,335&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;12,520&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <fil:ScheduleOfRevenuesByProductCategoryTextBlock contextRef="Y23Q1">&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr style="height:11.5pt"&gt;&lt;td valign="top"/&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;806&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;209&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,015&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,520&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;3,073&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;5,593&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,385&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;377&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,762&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,474&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;1,676&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;4,150&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;&lt;span style="font-family:Times New Roman"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,185&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5,335&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;12,520&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
</fil:ScheduleOfRevenuesByProductCategoryTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">806000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">209000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_ProductOrService-Obstetrics"
      decimals="-3"
      unitRef="USD">1015000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">2520000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">3073000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      unitRef="USD">5593000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">1385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">377000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_ProductOrService-Neonatal"
      decimals="-3"
      unitRef="USD">1762000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">2474000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">1676000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      unitRef="USD">4150000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">7185000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y23Q1_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">5335000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Y23Q1" decimals="-3" unitRef="USD">12520000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="Y23Q1">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(7) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie&#xae; Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represents an identifiable intangible asset which is being straight-line amortized and recognized as part of G&amp;amp;A expenses over the 7 month remaining life, as of the end of 1Q 2023, of the prior CSI agreement with Femcare.&lt;/p&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc"
      decimals="-3"
      unitRef="USD">21000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <fil:RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem
      contextRef="D230331_DistributionRightsAcquisition-CoopersurgicalInc"
      decimals="INF"
      unitRef="Pure">7</fil:RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem>
    <us-gaap:EarningsPerShareTextBlock contextRef="Y23Q1">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(8) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of first quarter 2023.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt; The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;(&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;March 31,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"/&gt;&lt;td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2022&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,214&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,534&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,628&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,655&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,636&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,665&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 1.16&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 0.97&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 1.16&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 0.96&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Y23Q1">&lt;p style="font:10pt Times New Roman;margin:0"&gt; The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;(&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;March 31,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"/&gt;&lt;td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2022&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,214&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,534&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,628&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,655&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;8&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,636&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,665&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 1.16&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 0.97&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.5pt"&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 1.16&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$ 0.96&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss contextRef="Y23Q1" decimals="-3" unitRef="USD">4214000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y22Q1" decimals="-3" unitRef="USD">3534000</us-gaap:ProfitLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y23Q1" decimals="-3" unitRef="Shares">3628000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y22Q1" decimals="-3" unitRef="Shares">3655000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Y23Q1" decimals="-3" unitRef="Shares">8000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Y22Q1" decimals="-3" unitRef="Shares">10000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y23Q1" decimals="-3" unitRef="Shares">3636000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y22Q1" decimals="-3" unitRef="Shares">3665000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic contextRef="Y23Q1" decimals="INF" unitRef="UsdPerShare">1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="Y22Q1" decimals="INF" unitRef="UsdPerShare">0.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="Y23Q1" decimals="INF" unitRef="UsdPerShare">1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="Y22Q1" decimals="INF" unitRef="UsdPerShare">0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SubsequentEventsTextBlock contextRef="Y23Q1">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(9) Subsequent Events.&lt;b&gt; &#160;&lt;/b&gt;UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>38
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MR#)DY4)5H,7&-O*#T&0+=IJ1<:,T!VA_)80^!.:"YE,0_0902P,$%     @
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M&++T+":]$72KCS-65 @:Z\L-1B%F2D!^OZ94'&_4#^0G8H/_ %!+ P04
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M0@#O5Y8?Z6"$!.,8+_X!4$L#!!0    ( ,%BI59[D ,W80(  $@%   9
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MN*'FH$/["!.K6G]EU\I2 _##FCHN:A= WTM%_W(W<1OT/3S["U!+ P04
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MZ/PB"T!W#=QMK&I\TZR5I1;TRXK^/-3.@<XW2ME^XP(,OVC^%U!+ P04
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M] UZ?8-S[-G_OM$IW6>93^N&6U6AL3R'A]H:7B \/<(/99F AY6Q:#7/#5S
M.!S1&(=7-$9^& WARU[2WQ*JW =WKA:U,K4N4>^#)]UL0^P/XQ 2/TP3&/K#
MJP2^HY+,<4=^,AY"DJ:T2D<QS(52!>6(ADC0_2%NE>:R!"8+N,YS.B";KB+V
M!^F 4*-T! ,_&H:=V@M(_8@X+RA4DK@Y:N.?>I/@J+ J)-6N?1C(52UM6V/]
M;M^AKMO"_.O>MC?ZGR67!@2N"1I>ID,/=-LR6L.J;5.F*V6IZ)OEAKHL:N=
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MQ/LHO%,?'M5/PZN$CU3U233X0,(@C,[HF?T[/+PB)^J2&3F^Z )?F[)SB6F
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M*+2M[LW"/D:@78 ]WRJ%1\?U^_"\I6]02P,$%     @ P6*E5CKYE!&O!
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ML/0!>7]-J7@[20L4>ZSS_P!02P,$%     @ P6*E5DT2=^:@ @  ! 8  !D
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M2Z%-$W##TK1IE#; [*^$T+N)/:!O_,E?4$L#!!0    ( ,%BI58\B%J8#P,
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( ,%BI5;FJG<<Z (  !L2   /
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M0D(VPT<8K$]YGBXTJR[-^:G;JW:V=9GG(ZR;RUO%L\.WC<-WF>M?4$L#!!0
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M4$L! A0#%     @ P6*E5A,+6:R> @  9 <  !@              ("!$Q0
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ,%BI5:;5RF*
MW00  ((2   8              " @><6  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " #!8J56H.\GHHD"   6!@  &
M@('Z&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ P6*E
M5H&5(:Q[!0  91\  !@              ("!N1X  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( ,%BI5:$"-IZE@8  !T;   8
M      " @6HD  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" #!8J56XJENE7 #  "#!P  &               @($V*P  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ P6*E5J_%2TB/ @  T@4  !@
M             ("!W"X  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( ,%BI59[D ,W80(  $@%   9              " @:$Q  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ P6*E5MFJW,6- @
MSP4  !D              ("!.30  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " #!8J5691ZN:\D#   ["   &0              @(']
M-@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ,%BI59O
M,*"]J@(  *8%   9              " @?TZ  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ P6*E5E\P6!3T @  :08  !D
M     ("!WCT  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,%BI5;A:,=0K0(  ,,%   9              "
M@15,  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ P6*E
M5@>AQ+K< @  C08  !D              ("!^4X  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " #!8J56K'H$\( "  #"!@  &0
M        @($,4@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( ,%BI598L);V3P(  *,%   9              " @<-4  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ P6*E5F.[<\40 @  Z@0
M !D              ("!25<  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " #!8J56.OF4$:\$  !O'0  &0              @(&060
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ,%BI59-$G?F
MH (   0&   9              " @79>  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ P6*E5CR(6I@/ P  &@D  !D
M ("!36$  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #!
M8J56O;X)2O\"  ")#P  #0              @ &39   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( ,%BI5:7BKL<P    !,"   +              "  ;UG
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,%BI5;FJG<<Z (  !L2   /
M          "  :9H  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #!8J56
M_^2]XT(!  !%$   &@              @ &[:P  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " #!8J56JAT0L'8!   H$0  $P
M        @ $U;0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     (@ B "4)
(  #<;@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>47</ContextCount>
  <ElementCount>126</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples</Role>
      <ShortName>New Accounting Pronouncements and Changes in Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - Warranty Reserve</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserve</Role>
      <ShortName>Warranty Reserve</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure</Role>
      <ShortName>CSI Distribution Agreement Purchase Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies</Role>
      <ShortName>New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables</Role>
      <ShortName>Inventories: Schedule of Inventory, Current (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables</Role>
      <ShortName>Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables</Role>
      <ShortName>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails</Role>
      <ShortName>Inventories: Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - Warranty Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserveDetails</Role>
      <ShortName>Warranty Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserve</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails</Role>
      <ShortName>Revenue Recognition: Schedule Of Revenues By Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails</Role>
      <ShortName>CSI Distribution Agreement Purchase Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="utmd-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails</Role>
      <ShortName>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="utmd-20230331.htm">utmd-20230331.htm</File>
    <File>utmd-20230331.xsd</File>
    <File>utmd-20230331_cal.xml</File>
    <File>utmd-20230331_def.xml</File>
    <File>utmd-20230331_lab.xml</File>
    <File>utmd-20230331_pre.xml</File>
    <File>utmd_ex31z1.htm</File>
    <File>utmd_ex31z2.htm</File>
    <File>utmd_ex32z1.htm</File>
    <File>utmd_ex32z2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="284">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>43
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "utmd-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 3,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 284,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "contextCount": 47,
   "dts": {
    "calculationLink": {
     "local": [
      "utmd-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "utmd-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "utmd-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 176,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 6,
    "total": 6
   },
   "keyCustom": 2,
   "keyStandard": 124,
   "memberCustom": 7,
   "memberStandard": 4,
   "nsprefix": "fil",
   "nsuri": "http://www.utahmed.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000100 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureInventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000110 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000120 - Disclosure - Warranty Reserve",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserve",
     "shortName": "Warranty Reserve",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000130 - Disclosure - Revenue Recognition",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000140 - Disclosure - CSI Distribution Agreement Purchase Disclosure",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure",
     "shortName": "CSI Distribution Agreement Purchase Disclosure",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000150 - Disclosure - Earnings Per Share",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000160 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000170 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies",
     "shortName": "New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000180 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables",
     "shortName": "Inventories: Schedule of Inventory, Current (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000190 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables",
     "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "E23Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "E23Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000200 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables",
     "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "E23Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000210 - Disclosure - Inventories: Schedule of Inventory, Current (Details)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails",
     "shortName": "Inventories: Schedule of Inventory, Current (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "E23Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000220 - Disclosure - Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ProductWarrantyAccrual",
       "p",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "E23Q1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProductWarrantyAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000230 - Disclosure - Warranty Reserve (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserveDetails",
     "shortName": "Warranty Reserve (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ProductWarrantyAccrual",
       "p",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "E23Q1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProductWarrantyAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000240 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
     "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1_ProductOrService-Obstetrics",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000250 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
     "shortName": "CSI Distribution Agreement Purchase Disclosure (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y19Q1_DistributionRightsAcquisition-CoopersurgicalInc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000260 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
     "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "E23Q1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "UsdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "E23Q1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "UsdPerShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "E21_StEqComps-CommonStock",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "E21_StEqComps-CommonStock",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000080 - Disclosure - Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureBasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples",
     "shortName": "New Accounting Pronouncements and Changes in Accounting Principles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230331.htm",
      "contextRef": "Y23Q1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 11,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Voluntary filer"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fil_BloodPressureMonitoringAndAccessoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.",
        "label": "Blood Pressure Monitoring and Accessories"
       }
      }
     },
     "localname": "BloodPressureMonitoringAndAccessoriesMember",
     "nsuri": "http://www.utahmed.com/20230331",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.",
        "label": "Common stock received and retired upon exercise of stock options"
       }
      }
     },
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptions",
     "nsuri": "http://www.utahmed.com/20230331",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.",
        "label": "Common stock received and retired upon exercise of stock options, shares"
       }
      }
     },
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares",
     "nsuri": "http://www.utahmed.com/20230331",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fil_CoopersurgicalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the CooperSurgical Inc, during the indicated time period.",
        "label": "CooperSurgical Inc"
       }
      }
     },
     "localname": "CoopersurgicalIncMember",
     "nsuri": "http://www.utahmed.com/20230331",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_DistributionRightsAcquisitionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the description of Distribution Rights Acquisition, during the indicated time period.",
        "label": "Distribution Rights Acquisition [Axis]"
       }
      }
     },
     "localname": "DistributionRightsAcquisitionAxis",
     "nsuri": "http://www.utahmed.com/20230331",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fil_DistributionRightsAcquisitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Distribution Rights Acquisition, during the indicated time period.",
        "label": "Distribution Rights Acquisition"
       }
      }
     },
     "localname": "DistributionRightsAcquisitionDomain",
     "nsuri": "http://www.utahmed.com/20230331",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_DomesticUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the DomesticUsMember, during the indicated time period.",
        "label": "DomesticUsMember"
       }
      }
     },
     "localname": "DomesticUsMember",
     "nsuri": "http://www.utahmed.com/20230331",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_GynecologyElectrosurgeryUrologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.",
        "label": "Gynecology/Electrosurgery/Urology"
       }
      }
     },
     "localname": "GynecologyElectrosurgeryUrologyMember",
     "nsuri": "http://www.utahmed.com/20230331",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_NeonatalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Neonatal, during the indicated time period.",
        "label": "Neonatal"
       }
      }
     },
     "localname": "NeonatalMember",
     "nsuri": "http://www.utahmed.com/20230331",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_ObstetricsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Obstetrics, during the indicated time period.",
        "label": "Obstetrics"
       }
      }
     },
     "localname": "ObstetricsMember",
     "nsuri": "http://www.utahmed.com/20230331",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_OutsideUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the OutsideUsMember, during the indicated time period.",
        "label": "OutsideUsMember"
       }
      }
     },
     "localname": "OutsideUsMember",
     "nsuri": "http://www.utahmed.com/20230331",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Remaining months of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period.",
        "label": "Remaining months of exclusive U.S. distribution rights for Femcare's Filshie Clip System"
       }
      }
     },
     "localname": "RemainingMonthsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem",
     "nsuri": "http://www.utahmed.com/20230331",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "fil_ScheduleOfRevenuesByProductCategoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.",
        "label": "Schedule Of Revenues By Product Category"
       }
      }
     },
     "localname": "ScheduleOfRevenuesByProductCategoryTextBlock",
     "nsuri": "http://www.utahmed.com/20230331",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r133",
      "r235",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r342",
      "r352",
      "r358",
      "r377",
      "r392",
      "r393",
      "r396",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r133",
      "r235",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r342",
      "r352",
      "r358",
      "r377",
      "r392",
      "r393",
      "r396",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r277",
      "r278",
      "r279",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r353",
      "r361",
      "r396",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r277",
      "r278",
      "r279",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r353",
      "r361",
      "r396",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r357"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r137",
      "r138"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts &amp; other receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": {
     "auth_ref": [],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r275",
      "r385",
      "r386",
      "r387",
      "r398",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Total adjustments",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income to net cash provided by operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r174",
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r6",
      "r22",
      "r24"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization {1}",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r55",
      "r72",
      "r89",
      "r121",
      "r127",
      "r131",
      "r139",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r195",
      "r199",
      "r215",
      "r245",
      "r299",
      "r357",
      "r368",
      "r394",
      "r395",
      "r400"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r67",
      "r75",
      "r89",
      "r139",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r195",
      "r199",
      "r215",
      "r357",
      "r394",
      "r395",
      "r400"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r19",
      "r69",
      "r344"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash &amp; Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r19",
      "r46",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash at beginning of period",
        "periodEndLabel": "Cash at end of period",
        "periodStartLabel": "Cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r1",
      "r46"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Net increase in cash and cash equivalents",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r385",
      "r386",
      "r398",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r31",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r31",
      "r287",
      "r305",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r31",
      "r247",
      "r357"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - March 31, 2023, 3,628 shares and December 31, 2022, 3,628 shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r16",
      "r77",
      "r79",
      "r83",
      "r241",
      "r253"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Total comprehensive income",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r42",
      "r235"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r6",
      "r53",
      "r59",
      "r192",
      "r193",
      "r384"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred income taxes {1}",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r183",
      "r184",
      "r246"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxExpenseFromStockOptionsExercised": {
     "auth_ref": [],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.",
        "label": "Tax benefit attributable to exercise of stock options"
       }
      }
     },
     "localname": "DeferredTaxExpenseFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r26",
      "r397"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred tax liability - Femcare IIA"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r6",
      "r25"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r171",
      "r172",
      "r175",
      "r176",
      "r177",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Common stock dividends",
        "negatedLabel": "Common stock dividends"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r84",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r110",
      "r112",
      "r113",
      "r114",
      "r115",
      "r119",
      "r210",
      "r211",
      "r242",
      "r254",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings per share, basic",
        "verboseLabel": "Earnings per common share (basic)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r84",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r112",
      "r113",
      "r114",
      "r115",
      "r119",
      "r210",
      "r211",
      "r242",
      "r254",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings per share, diluted",
        "verboseLabel": "Earnings per common share (diluted)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r109",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r8",
      "r64",
      "r80",
      "r81",
      "r82",
      "r90",
      "r91",
      "r92",
      "r96",
      "r104",
      "r106",
      "r120",
      "r140",
      "r143",
      "r168",
      "r178",
      "r179",
      "r180",
      "r186",
      "r187",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r209",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r231",
      "r262",
      "r263",
      "r264",
      "r275",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r71",
      "r149"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Other intangible assets - accumulated amortization",
        "negatedLabel": "Other intangible assets - accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r51",
      "r239"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Other intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r70",
      "r146",
      "r240",
      "r351",
      "r357",
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r41",
      "r89",
      "r121",
      "r126",
      "r130",
      "r132",
      "r139",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r215",
      "r350",
      "r394"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r40",
      "r57",
      "r121",
      "r126",
      "r130",
      "r132",
      "r243",
      "r251",
      "r350"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income before provision for income taxes",
        "totalLabel": "Income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r58",
      "r62",
      "r105",
      "r106",
      "r124",
      "r185",
      "r191",
      "r255"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r18",
      "r20"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Cash paid during the period for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts payable {1}",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Accounts receivable and other receivables",
        "negatedLabel": "Accounts receivable and other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Accrued expenses {1}",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Inventories {1}",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Prepaid expenses and other current assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "CSI Distribution Agreement Purchase Disclosure"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r21",
      "r23"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Other intangible assets, net",
        "totalLabel": "Other intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventories {2}",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r50",
      "r346"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r73",
      "r345",
      "r357"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails",
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r89",
      "r139",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r196",
      "r199",
      "r200",
      "r215",
      "r286",
      "r349",
      "r368",
      "r394",
      "r400",
      "r401"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r36",
      "r56",
      "r249",
      "r357",
      "r383",
      "r389",
      "r399"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Total liabilities and stockholders' equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r68",
      "r89",
      "r139",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r196",
      "r199",
      "r200",
      "r215",
      "r357",
      "r394",
      "r400",
      "r401"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Total current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net cash provided by/(used in) financing activities",
        "totalLabel": "Net cash provided by/(used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net cash used in investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net cash provided by operating activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r60",
      "r61",
      "r63",
      "r65",
      "r93",
      "r94",
      "r97",
      "r98",
      "r107",
      "r108",
      "r141",
      "r142",
      "r188",
      "r189",
      "r190",
      "r206",
      "r208",
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r228",
      "r229",
      "r232",
      "r236",
      "r237",
      "r238",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "New Accounting Pronouncements and Changes in Accounting Principles"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Total operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r121",
      "r126",
      "r130",
      "r132",
      "r350"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating income",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Long-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r29",
      "r54",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r74",
      "r357"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r2"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation net of taxes of $0 in all periods"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r219",
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other long term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payment of dividends",
        "negatedLabel": "Payment of dividends"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Property and equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock - options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrual": {
     "auth_ref": [
      "r27",
      "r154",
      "r157",
      "r158"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.",
        "label": "Standard and Extended Product Warranty Accrual"
       }
      }
     },
     "localname": "ProductWarrantyAccrual",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.",
        "label": "Warranty Reserve"
       }
      }
     },
     "localname": "ProductWarrantyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureWarrantyReserve"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r66",
      "r76",
      "r78",
      "r86",
      "r89",
      "r95",
      "r105",
      "r106",
      "r121",
      "r126",
      "r130",
      "r132",
      "r139",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r194",
      "r197",
      "r198",
      "r211",
      "r215",
      "r243",
      "r252",
      "r274",
      "r307",
      "r322",
      "r323",
      "r350",
      "r355",
      "r356",
      "r367",
      "r380",
      "r394"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow",
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome",
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r244",
      "r250",
      "r357"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r85",
      "r144"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for losses on accounts receivable"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r28",
      "r182",
      "r402"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research &amp; development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r33",
      "r52",
      "r248",
      "r265",
      "r269",
      "r273",
      "r288",
      "r357"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r64",
      "r90",
      "r91",
      "r92",
      "r96",
      "r104",
      "r106",
      "r140",
      "r143",
      "r178",
      "r179",
      "r180",
      "r186",
      "r187",
      "r201",
      "r203",
      "r204",
      "r207",
      "r209",
      "r262",
      "r264",
      "r275",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r122",
      "r123",
      "r125",
      "r128",
      "r129",
      "r133",
      "r134",
      "r136",
      "r169",
      "r170",
      "r235"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Sales, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r308",
      "r341",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r37",
      "r38",
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedCondensedStatementOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Equity Balance, shares",
        "periodEndLabel": "Equity Balance, shares",
        "periodStartLabel": "Equity Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r8",
      "r15",
      "r64",
      "r80",
      "r81",
      "r82",
      "r90",
      "r91",
      "r92",
      "r96",
      "r104",
      "r106",
      "r120",
      "r140",
      "r143",
      "r168",
      "r178",
      "r179",
      "r180",
      "r186",
      "r187",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r209",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r231",
      "r262",
      "r263",
      "r264",
      "r275",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r120",
      "r235",
      "r272",
      "r276",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
        "verboseLabel": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r120",
      "r235",
      "r272",
      "r276",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureCsiDistributionAgreementPurchaseDisclosureDetails",
      "http://www.utahmed.com/20230331/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r30",
      "r31",
      "r52",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Common stock issued upon exercise of employee stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r15",
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Common stock issued upon exercise of employee stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock option compensation expense"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r8",
      "r30",
      "r31",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Common stock purchased and retired, shares",
        "negatedLabel": "Common stock purchased and retired, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r8",
      "r30",
      "r31",
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Common stock purchased and retired"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r31",
      "r34",
      "r35",
      "r49",
      "r289",
      "r305",
      "r325",
      "r326",
      "r357",
      "r368",
      "r383",
      "r389",
      "r399",
      "r405"
     ],
     "calculation": {
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Total stockholders' equity",
        "periodEndLabel": "Equity Balance, value",
        "periodStartLabel": "Equity Balance, value",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet",
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TableTextBlockSupplementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tables/Schedules"
       }
      }
     },
     "localname": "TableTextBlockSupplementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Dilutive effect of stock options"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r111",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Diluted shares",
        "verboseLabel": "Shares outstanding (diluted)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r110",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average shares, basic",
        "verboseLabel": "Shares outstanding (basic)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.utahmed.com/20230331/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20230331/role/idr_StatementUtahMedicalProductsIncConsolidatedStatementOfIncome"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org//260/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org//330/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//350-30/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(5)",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(5)",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r369": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r371": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r372": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r373": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r374": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r375": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r376": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org//250/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>44
<FILENAME>0001811884-23-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001811884-23-000013-xbrl.zip
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MF2Y??^Q+>^"/8^#Z M^L7G_MZ!Q)_*63W,"OMO[\-/6C\S\2T'$Z1VT.'W+
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ME4A/]I8/@4HI,(J7(#(EOTSJ'"1%57RB346LQ-N6Q\%^;\1VL]:66YNZ/O9
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M..UK8DJUO#*T#C2K;[&6U[Y;![9@&V@II82J/0?3P+9, UD;!M2:4EG;"7;
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M!SZ(J!>+U%"*\<2=15Z)KF!N Q1Q1"46Q2[@B2__C&QC-KD.*NY(>^14<A7
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M2*8,$RQ1B5#'502SBRV)D(@?@EF8F@-D*#86$O4R2DX@EI7D&:MK'*0*H!\
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MPN0#X;*6=(CZ^OEFOE-,V.E/BQ_2+E8BU.7.DB!.E1^%BN9&P"XZBBW=2@)
MPP9<LN09=@Z;-:T2ZE/8>VM%*S E[+@FZ_7 <E[<&4RV>'F:M=**T?"ZW'7)
MP6LVZNRX(6=^YM0U:T#']24G-%ZQC$JZS%5T$15@PGYWP*86UH1,JE%-AP\F
M#@ZR;INL3\K_>:!7F@UD".HZ0*]4ZMAF;RF?VQCH"VM"N-1W5Y9(*CZ)/%16
M4JQ6V;$:!U<,1BIJ/>H2(GX)C!;6A#!2M]Q1#938,7R>*HNZQASG7-:Q<JZ@
M4U)SRI6B8%E/RJ!D6_SN'#2%7-X$<G=$U@Z &:T]"4 0\=O/:9ZB&M&KZ_\<
MJNV\KYCKI9'$NPT;"@2 )._\^5H$55;6:2:SHZ55Z@G8#(8.+/UDZC_*]/P&
M<FIM5&:41+Y&Q' V,Y>3PEXW1$2VO;ZD%BHQM!U?>@:)&3M>U0[/6$QGB?X;
M;X?S5Y)=G0.\ZN9D[CR>PJ4X#,P4F^-QRRD9S=P5H:A5RCD_H-]F-Y#="LCJ
M.CD^F<Q<3RH3M!<GLVV:[#IFR FN8WD[")M="IH;Q*/F>A^UA+O8#KF Z-*Q
M>'E?0^/*Z*Y CKD=SEZ*-<3<29)]6W2RF3GJ93GE1!N+L^!+0)-2$.9 =D%Y
M=55" QV%PB]PBM!L=SQK2#%G,I\7^+)K"W>IO+[H2!0T)8A%'LS6$PLZ*.8^
M<JUUB%Q[CY%K?*/ CBO;*MCAX93GZ)3%OS;(&+Q](^X5]\C5M;! :GAF+?PJ
MUJG$(T-$W-NX;UBA>U6-Q&?0,Z9-@65P&+ ?!K*+OF;]8$,XYQ\QT"I\VG;D
M),%[KOSV03,L-PAV&P._\,-0"I !/E%7Y_Z6D=>.!N]CI[Z!8'/41.9W$=>%
MCE+YU.R!L/U?-(K@8]#2)KHD1W)="NSR/>J/0A$H "5L&V98CUSRYA!<]E0S
MJ060".G#OG&T.P.8CAML0\9/A6%B'A^,+,KZC33O&1ON@)NP5(Z]G<0$@1-@
M$9M&LG.CWE3G_)!+G!;"'3&-A.E%F\M(MT301V(!IJMB/BB^*PQ E'1![J.9
MJQ=I3+3$^%"OUA>>#C9/;8LTT[5GT/W0"IY^#AXA2O'G9)0FK5^9=35 _WKB
M+&+H /7%H+69)D8'R6Q2I.<#1<8E0TNC X#4]J'"9.\W[!D9\6G'3@0/5(*%
M?AJQ$['=WEVI,-WA1DQ7.M<^<X1#X&J[TYY0@>E\OCO9/J>%6>-<4^BH2WDL
MA?//.0OGXM<"@L&AZ5C7%%5ML>-J*1Y0,.^SK)3(9]E<YK/$@_^AUFQAK[T*
M=3J29RDZ8>*97@AE^5!O5%:=1 I%B?68(9_G\M,>#=X=#K&=2"RR=B-OZ:X\
MIPA?!"%VD/.T$?LN&ZK=A$'B@.YBK/49H;>LU.KE%0%<+;6^@,?5\WR#"]2Q
ME'PG- E*4%5I+9]'/- L+9TJL/]]I1:N-$/P%7PH8G]=XIW!E[,6NS? :N$1
ML1 4TA3RE;@*_/58K;46"3=*H\LV'K;W)3CC;-A@2:TUETTG?HXU$]PN[^C>
M7;:I:RF=(HSS:;=OV)@* HE84<G_791:0P/NI**7;C2$$D6N[7O8D5"F/<-^
M1$0WB9@A*' 6A@4IV#L4N__@,Z#+&R[U"7;X@^8(IC479X>AIAJU+!3?Z(9'
M:\$P;^T))-:C 9=0ZIJ:''T% XKQ9JO1,=)K8&@B2&T^?@\#RJT' V\5&FB(
MLK\AM51D]B1ZZ)4(1B/,$^F#Q]80RE ])BQG(I0$-6R)1#).%_*F(&KJ6+8^
M#/O.SDV):)0M$(.>IG4XMJVYJ$BETH@&1J*NP9H8<1O<E(OL.U"P:%K,^MPT
M^&,0,^S%S@#1S8SI1JDA[/^$)@)L!DRO&^Y"$+XV&,'X1"XHNP21 *;M_K]%
M+L"L12@<,HZ-ID5@O\@,T-RP%:DY#68EI0Z'([G1ZUPPM53XG=URC(J>RV'!
M9H/4[-;$ML?>3VX^!NU,Y08%=VQBQ,YV-9O8.J,G<Q4!((Q%.ZQQ$!7)3=E2
M6/+\N5Y="N. A. I?$FFM"#R@BE%+^>S=**1#W$UA[B:',35 )/.FTD_"%@A
M73NOBR,E/Q].A,N(&-]U4$UM9T$UU:0F/GER&D:]]NVHKI73D+:#]WY%=I",
MHGD9'@_1-+NH[DHF$/0)7. U:!].X':ZR6VPH!18;"JQP'0'O19W4#3I _+R
M< 1K:S0PR(95YSV@M!M<XW-ZT@IY7E"*)VW.XUS"$>8O*AL&<\],.D&?[XO
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MND%_0$,D_5MCD2O=_5IZ^6=//-$F5H/P"A7^QH]^90\$SN](NOQ#9S_XK9.
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M.90A3L_P#Y#4X)_C>I+]_H__ U!+ P04    " #!8J564VI:!%<(  !71
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MK*8C.-F1=#CR(7IO(*!_LA.HH5>/^M/ _/4IW346JB*#&_BA#UW@ZX0<,%'
M// B2;26&[ %RC87SN=N7*":K[V=BUK<,C4MCXR<H$_D;8AL(.MWA(Q"L1K@
M*QF]$QHQ-.#\C3^;4H*2K4 (E#5JVR>WX)_4TFD:FQ:Q1>2@R3S]I_/?@(Z)
MCV+(IFH1(:88);\0/P"#Z,5X8RK%7*(IDMH1X4:]X+^A/]2,XVI.T9#!<!BV
M5L>P.8SX^X(/3?:-^N1EM7 "B1+QD>Z-^#6'"P_$?$:Y!QWK9R\V#F#3=7F
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MK!T4U^#[^@0",)19[W0TO2%E5"JMP1CF&IB*,,68;4%MV=T2E9B"=K!U3/5
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MY**1I*ZA <HXBQPB.0CSOD V1PA-0IPMXBL9?Q*R'#(<?3 '_AD-?!([]]&
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M>GMQAICJSM#;L]^_^29[C \?8Y<O73[FS?$8RT J4GM-!4?Q>O=3XB%+7Q8
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MJ#Y0VTE(U$=HZ/UC&R?LV". 35MJG?31TI\%"(*,"ZN_AI=+["9-FC6> IM
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M5$':;:F!K0*P68#B5#+6S"2USVBBW-//_1GB J05\94Y6B>YUL)45[G\&D!
M3TU!'G&XQ;?8):N0N_QN2."[.Q7$U<_!6X5H2@:!;<8$%;A8!DQM-51;B#19
MH7Z]NOIU5*2/&//C=E0[):?OT_O.O]_\Q^BITXSD"8[$F:D%\2W;%#K3%WJ=
M;:[TDO4G;%_II8Y 1Y5>)+*:KO1R_G++LKW\\&NTS+GV6O,%.-?&-5_:3]BB
MZB\2I6E6?U&AN2<W]2;"KB^KHWXT!.YHKO(#W0@+]"P#3MU4JQY@@6[[/!\S
MI_.(A-Q:_,E/'D;;."%K'.W-$LQ00?_GB1-ZVE R=(9N(SWH,N@$V$JC%$ ?
M@N-UZ^7LNU%]??:"9*#!YO,&,Q86[$N:U35*4'#@8? , )-<^JUO(_XI-HI8
M!>5]H$!.O_=*<9.$HR'&[HV&FB#H7;3ZDE(-8,O 6C=1X>T/W'FA;0V$85A.
M5Q[2,V\4[>A'0MI;5>M9$S4-M"4$UR[XREEOOD-L3=)$4]M>?XVT49?"WFS!
M.LM@''H>:[7.JR'-(GZ["BLP4 Z'9S#*Y3"0P9@Q*)2XRIE8@BQ=751S&#46
MI3/\_$*";9@X+%,CP)&X=41Y'!PQ LX0J.Q)HB6C:1TP!%.N(D*F[0X]X3=Y
M_.J8(E'B$C\>9\(W7LO9B),\I8PFS"]):5N$">G<ZQSG8K5WUV &LXMO, T]
M_/0S%I>\*X\ST%*FGK.!+TE&&7'2B-*V"!/2N==TCY&H'9 43=;TU.:[=_%'
M7--7K'8(*-U9P ^V_X]IFDIF!HC:-'.YQ.J9I2H+%'64ERP#42^WMF' Z68M
M27@]O6+%/7D:@>;#T'M;,QDA>V;/*0WI&=Q7"C"BB95QXLU45+[-M5C'?I(0
MHI439FU*1R2,2>![3E:*_"9]4_ ?9\O,B>8$_ K!K]OZ\1?&V8!3'CJ:-V1K
ML)@N7DJ_*(!ENZ KO562++H$3#^5\WE'KMER\N0^T%7&M^SB'791QK0+3N"*
M_=W-'G0ZW[=)PYE@*&*6GO3O=/.%/(;"LDW7H3(K5?8[QI)E45&*E+L6A/J+
MDC*9I#<:SG]"EU>S3W-T>3O[B"ZGU\/KT?3Z QJ.%M-?IHOI9&[9IFBOJ/91
M0Z?+],L+&*0YJX<R!N_3V@X"_*J>,E7,0B$5+.PH99%E(F?]AOY]83(,UN T
MI)&PM7.Q;%MIZD)48$,':>V-1H4,R5OL8O\1>_S+D_B4]=V&W:/2*AZS9;&V
M1YI-66-A@M&#F*.,S,1 -FU:]R7*1."9-5$J!-I2*<0U8@R6Q>A5'PT-9*;4
MA%Z&O#LM'\!_\_7SLK496:"B8<[<WNOG.L>KJC";#0DI.FK+=LK'@J]4,@D,
M%.S94[8$=5KSKMQ?E*KO)Q$TMT5DX'T@ 55:G$JGN'3H/0M.\FPB(01==XOA
M3^CC9#P=#:_0S>UL?#=:S,_0]'KT"HUFU_/9U70\7$S&:+Z@?WR<7"_0[)+^
M,!O]_-/L:CRYG7_E;$C\'9K\\6ZZ^+-EX&RDQDIZ9^.5[BE8/<94!>Q2/\:/
M.""\L)_<3R%_!AZ KB$1+($S99"%E'D')I;A34L3U2!SW<7IS,<_>>*M(=($
M4GZX$;KY:X;"/?UB_J OYQ,ZD,VB0"P!C,[4J[Y^A>X[@$<6[7WIQZX3_)G"
M5!P9)!P*@8>*/^B.E07HI\01HVYCC)!*!468:*U!1Z7RAT]^W25>_4QG9?*+
M$H&,7/("\NBOC-'?^JB5WW1&#:_3'H[=R.<W.783_O]3.+^H5^VR^17PMM]8
M'W8A=DE 5KM)@-TD8M[1%8YV=Q'_I3 &2^\YR 9K)!EDDQT8G1]S.L]8&=I?
MQB?4<(\IY_F\ME4C=1:W5G/H]M,A("+>UDT^.1$]:=%KGNM&6T=42D\P&%SY
M7RH#*&>75>EUHM1$.GE*<,@J$63\4,X091PM@9F>6BHU\=5KTPN@CFL_S;>;
M3<"-"@HSD_(Q*,ATY0+E\3(>\7E>)\LV9YJN"LK0:K0V/;<AWXNEP)?L"7/M
MPX72@&K'D,0Z*&E,6=SC6[X"_41!>QX_TSK!C>-[TW#D;/S$"6H/GGK/@&.>
M=20"A3KO&2#&8>"'*.-A&;:T-%&):-9>G)Z2]YL$QG05$--A( P/3XK917E)
M(ILC2!I&CIB*&#%?3'T:QUO]0NK9:.-%U(^E,!#R<51 _0RE]"W#D$(+RLKI
M-8O1D]^W[,83.GDK ^$>71%OT F;EYJ)"[0S=RSF+$QVQ0')KU$OQ_Y)M&A.
M],C*0%@V@0;-B53BG\:G+U)!U8$OW<6G/%@77HG-3M?%!SLZ8M?(9NB<O<G.
MV>YS.F?7J$/SL"U:JWZ QYLJB,"5_B,80$<\X-^QM-&%P==E<P$U/E1**4\"
MWJ.95@!:7>^NRQ&-Z%]GT8)\+H=ARD8:*T)4Y6Z@:L2^_A"CSLH/,?J6X$!#
M \*J0X(%Z PA-]O[P'<O ^*4#0#U8^"HJ.$(NNQS<HC3LV[]:^9:77F1>GOY
M-+&.X D.6$QYN0E0UK_8NQ!\N+0>A7[6FL@'@5'*9W#%DQ8.G%#*"N6\+$%8
M&^V4OT.-EZ\]'N,H*6"1_G3 (?TA=P_&P]";X^C1=W%<FS0@']L6:5H2 ,V1
MW*7+_+P9=4M@I#7U'#?ZVN_'?K2]C_$_MRPZEQ4:C94MHH3CP=8DE22@*($]
M<912MP0ZVI.O& *TUJ$_$^0MWM#U?6!E9@Y)56,>]9.&]=:F1+8B8<1LV5!>
M8XF/>Z[%E+XN.GZ;GN2[=)(A7K'8+=%UTLA<3V:":ZBO6N-<&Q3WMTU3-T55
MG&+"8YX&*7)$M2!D9,NVDMW8QO4Y]VKR+5YO K+#N'&R\LE0WDJ/M5AO#X)>
M$/\)L_AFN@\?<>2L\#7/AYXM4QEGVR1FH8-4=-[:4 #V9C2@.&\E,03B.4/D
MI!PSV)ZA>\;!X/>HLYE1>O=$7 $CZ]I-#AS02SZWKRW;FJT45-Z5[=':8\C,
M%8GCO/V,'VZI.%F#>_JV>(^7),+[" U,7Q])Y-"U\$,GVDT3O(ZOJ2Y9XQH2
M4-%6],Z-Z=SD83?=<#03NM.I-B"OAI0MNN<RI#W>F@8#/5.-2!TF!M1RNABI
M3E5;'V?5_=[K.U;KQHEF$<^D]WA+C+Q#LN 5I/.DP1@NE73FXKDH)^8Q2GDA
MSNS0.=LR^#=0D"342VO]3M0@31$<+WG ?,,THX4"GV'/,56<O.9B=.:M9/TW
MTK.AT%E9& +W55;Y&7!=,Z(HI6H)(&03KOHK!1KNI[:4$X7T<QKG+S"5U5\\
M'EQC2B4)""D9<6L_2\K95ZI-:2W$*6O>ILW1#-2\E1'JJ.:MANR@3UFIYNWT
M^I?)?/$<:]YJ*$JSYJWN*O=EGXBP$^,Q3O^<AD/7)=LPB6^<'<N0%%L9%,\9
ML!7H208*:\U(HDU*TW#16Z-SD):]+4_$LDVEK8B:&W4#G/43D^NZV_4V8%>B
M6?* (U8(,<(/.(S]1WRP *0W?7K'%T5!-:<#CO1M*SEPB^5,$6%<D5MDBP+*
MT3*TMM93)6(7M,2G*7I>N*F)>S2KGC)>]+Q>*@@NGV6A\'HU* N%2U:GGPY(
MJ?TS7%VQ=W@NS8Y9.J6][M7/@7L4Z4H&@=H5"5<#^OE>HX!QV1MV;&E8V%@9
ME4Y"C=:IZZ2%&Q(G3O 7?S,BGK*#\O%@8ZD+M3*8S%Y(&2#* 3$6EB!)3P_"
M' ;Q8G38+/>/6R>BFS/8W>(-B>J2&40C333,%7 '?=GREKE[VB@E;A%(%-.O
MZYHKTWYGKY1/. A^#LGG<$[?;"2DWU06 "0V(HO&PU\L"DE@(3%!,/B5T48Y
M\;1D@7UF9H46JF\6G07I+#]ACE<,N1\P647.YL%WG4"8GR >"\E/4$H P4V1
MJB5(T9IS,3%!3^W]A*MF%=9F2V8B#"F#7>8K.ZY5)C@L:S\.#DUM*"<HBR'C
MQ>).]]S.4,;/$M"U54PEPK3-"O;D^?B<V=U8W&M$0OI7-VT$>D,"W]VE_U5!
MM#$9N->CG=P0R%*>Z, 4'7-E!W?&T3+DMM53U>4!6.!3(WD8>J.T1^G>RLS'
M^*'K;P*L3!0S0KI#Q#>>7V>[@&?'9+(@/SP>F(OS?+9(8\4VV#;MD--/@""D
M8VV:/%%U[[C!EH5K%WOCIOUR!9NN9R' 88LGT1EL(R?,1,Y9(3_MW<SW+_\+
M/DAGT&]JKY:D@=(F5'624-&3J+L2=7JZG7RB4(N]V3PK-:6(&FI P'SPA4I6
M4)30X21 <C99@2:^?>P-A&VN)W6 @]:B]M5&8>DGS$,M0&1A@(%V"25>!CY:
M9&VR;&,[$76^&'(Y3P'LZEQK6C/4K7V/677[UH[J]V;M:#/9;$(I(/AMU]"3
M_O/LX\1X=AIHAHID5<A$T8 EY%"Y'G!BD0E:4WGUN6-RE/:=:,.J]>A66U8^
M9C#I1BH79-^EM2$+YPU^_NBCJ+')V6F4OS0QQ1-G'DG5),D_4J.SKS#28ASK
M2!H()1AL("!4(H/)P&K+8"2?>$T8ITK[_831L1C2M-">'"XU \&!<D+>$)C,
MTH#@+.'1RIJ\XHE7HN#D6N^Q8+3B0%P:9*: M,GC[W ^GRQL2PRJGV9]D>:^
MDEM9T=]AA!U!I./1/X,Z.-?P 5E\>"PC)6A;\&+=1(]Z,XLTVED$6J7O2J&H
M3<V2:SP$CT73D<E L&M=,QU48&41;O3U4@U1TUZLGFPKQR5]:SK<">TLZB?A
M-A=MZ4#OI_GTN''V<!5A?B]'-UFM0W1@;0D.6^BH:H1HMH26I5T+ S.T"?27
M9FW*S,U]B]N8)S+1_V5\D+-G9-!(T<WLE!9RR!3M3B$7!X2T0FS?=:&DG46K
MXPS6?#+70;1XR+ ,1\+Y2@HVG:HW:$UJ*P7Q;+EPGL3X$#YA "DJ:>!FXN,\
M9N/N1D-ST# &-YS(B;:"2ADUFT(+7_UFP&8=6$5'E>HX8QFN9<[P#7 (UL 9
M;8/P!\FM ?I&PI\T&[>L &'V;2UF>H'W+4X</\1>7JRI4/A@C)>^*VP2K?$@
M= /HRP;9$3D7A#,VEJ%)7PME>#5<HA/U %:8O"4/F.\);-(4/G\FCEFU%M2-
M74\7\T Q'6VQ5ZU2*?;'"L8;<,G*)0%Z91EQ6[]XRKG7.&8UEJ%7=_XM=K'_
MR-S$[ ZOY=2O?<24:U\FCQ$'_U?.>O-=5MDIVC.+SU"(;<O/U-&)R/>O7*0.
M'$!S[&XC^EZ\>'._\)-*+;[:(1#GCH@?Z*; "+'LW8LW+^^_1CD+2Y AFW71
M42-5<V>NO\D:1RMZY/H0D<_) [O/.F$Y_$XU&N[LDTIAP,N7TT<I Y1QL @A
M&GJH>O74R]%IL>MH1 _H*Q*)\7(\RDS)ZPI7 _C@=%%.V#I8U$Z[OO;UL;:+
M,[FB?_OQB_PW]#_W3HQ__.)_ 5!+ P04    " #!8J56ETJ2C)@7  #8? $
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M,,$URJ\;W! X=(EYZG9P<6 YO#.;H3)+W049 ?4-E 49W;DN13]%8AKT:>D
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MI$:;=GD.X[&CJ(B$VD!5[ 0M5\;?J@*2^ OQSX/%T"_?_S]02P,$%     @
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M;60M,C R,S S,S$N>'-D4$L! A0#%     @ P6*E5M&#J>Y^"0  2'@  !4
M             ( !AH0  '5T;60M,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( ,%BI5;Y:VC4A D  &-Q   5              "  3>.  !U=&UD+3(P
M,C,P,S,Q7V1E9BYX;6Q02P$"% ,4    " #!8J56U&<)MZLF   ZX@$ %0
M            @ 'NEP  =71M9"TR,#(S,#,S,5]L86(N>&UL4$L! A0#%
M  @ P6*E5I=*DHR8%P  V'P! !4              ( !S+X  '5T;60M,C R
M,S S,S%?<')E+GAM;%!+ 0(4 Q0    ( ,%BI588,"HL\ 8  )H;   /
M          "  9?6  !U=&UD7V5X,S%Z,2YH=&U02P$"% ,4    " #!8J56
MC$ T8^L&  !:&P  #P              @ &TW0  =71M9%]E>#,Q>C(N:'1M
M4$L! A0#%     @ P6*E5C$@RGXW!   ]PL   \              ( !S.0
M '5T;61?97@S,GHQ+FAT;5!+ 0(4 Q0    ( ,%BI58P2I-Q-@0   $,   /
M              "  3#I  !U=&UD7V5X,S)Z,BYH=&U02P4&      H "@!^
) @  D^T

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
